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ABSTRACT 
 
SMOKING AND NICOTINE ALTER UGT1A EXPRESSION 
Gizem ÖLMEZER 
MSc. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. Dr. Özlen KONU 
August 2011 
The expression and activity of enzymes taking role in drug metabolism are important 
as in the case of phase II glucuronidation enzymes; namely UDP-
glucuronosyltransferases (UGTs).  Previously, it has been identified that smoking 
upregulates the expression of UGT enzymes in oral mucosa. We asked whether 
smoking induces UGT1A expression in other tissues and re-analyzed publically 
available datasets run with samples from smokers and non-smokers.  It was observed 
that UGT1A enzymes were overexpressed in several types of epithelial cells of 
smokers.  
30% of nicotine metabolism is performed by UGT enzymes; however, whether 
UGT1A expression is modulated by nicotine, the addictive component of tobacco 
smoke, is not known. For this purpose, the expression levels of UGT1A isoforms 
were measured using Real-Time PCR in nicotine treated SW620 colorectal cancer 
cells.  Our findings showed that nicotine’s effect on UGT1A expression was isoform 
specific; and the magnitude of modulation differed among isoforms. Furthermore, 
the upregulation of UGT1A enzymes could only be observed in serum-deprived 
SW620 cells. In summary, nicotine metabolism enzymes are regulated by both 
smoking in vivo and nicotine in vitro. Nevertheless, enhanced xenobiotic metabolism 
may result in chemoresistance, which is undesirable for cancer patients. Therefore, 
before drug therapy cancer patients might be analyzed in terms of their smoking 
status and UGT1A expression patterns.  
Keywords: Nicotine, Smoking, UDP-glucuronosyltransferases (UGTs), Serum 
Starvation, Colon Cancer 
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ÖZ 
 
SİGARA VE NİKOTİN UGT1A GEN İFADESİNİ 
DEĞİŞTİRİYOR 
Gizem ÖLMEZER 
Moleküler Biyoloji ve Genetik Yüksek Lisansı 
Tez danışmanı: Yrd. Doç. Dr. Özlen KONU 
August 2011 
İlaç metabolizmasında görev alan genlerin ifade ve aktiviteleri, ilaçların etkilerini 
değerlendirmekte büyük önem taşır. UGT genleri faz II metabolizmasında yer alan 
enzimlerdir ve sağlıklı bireylerin ağız mukozasında sigara içimiyle ifadelerinin arttığı 
gösterilmiştir. Bu çalışmada, sigaranın UGT1A gen ifadeleri üzerindeki etkileri 
başka dokularda da geçerli midir sorusu sorulmuştur. Bu amaçla, GEO veritabanında 
yer alan mikrodizin çalışmaları tekrar analiz edilmiş ve UGT1A genlerinin birçok 
epitel dokuda sigara içimiyle arttığı gösterilmiştir.  
Nikotin metabolizmasının %30’u UGT genleri tarafından yürütülmekte; fakat, gen 
düzenlenmesinde nikotinin rolü olup olmadığı bilinmemektedir. Bu amaçla UGT1A 
genlerinin ifadeleri izoform olarak mRNA seviyesinde ve Gerçek Zamanlı Polimeraz 
Zincir Reaksiyonu ile nikotin ile muamele edilmiş SW620 kolorektal kanser 
hücrelerinde tespit edilmiştir. Sonuçlar, UGT1A genlerinin serumdan uzak büyütülen 
SW620 hücrelerinde izoforma bağlı olarak nikotinle beraber arttığını ve bu artışın 
her izoformda farklı olduğunu göstermiştir.  Özet olarak, sigara ve nikotin UGT1A 
gen ifadesini düzenlemektedir. Zenobiyotik metabolizmasının düzeni vücuda alınan 
her ilaca verilen cevabı etkilediği için, bu mekanizmaların anlaşılması büyük önem 
taşımaktadır. İlaç tedavisinden önce hastanın sigara alışkanlığı ve UGT1A izoform 
ifadesi özellikleri açısından analiz edilebillir. 
Anahtar sözcükler: Nikotin, UGT enzimleri, Sigara, Kolon kanseri
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1. INTRODUCTION 
1.1 Glucuronidation 
In order to maintain its stability and homeostasis, a cell must eliminate non-
membrane associated substrates originating both endo- and exogenously. For this 
purpose, in mammals, many chemical defense pathways have evolved, one of which 
is glucuronidation 1.  Glucuronidation is a process of conjugating glucuronic acid to 
the lipid-soluble toxics; this results in formation of water-soluble “glucuronides”, 
which, then, can be easily transported to excretory system. This crucial function has 
been performed by Endoplasmic Reticulum (ER) resident enzymes, UDP-
glucuronosyltransferases (UGTs) 2.  
UGT enzymes catalyze glucuronidation of a variety of detrimental substances for 
removal from the body. Among the lipid-soluble substrates of UGTs, there are bile 
acids, bilirubin, hormones, steroids, free fatty acids and xenobiotics such as 
therapeutic drugs, environmental pollutants, and carcinogens; including nicotine and 
tobacco smoke. Since almost all of the glucoronides generated are free of any 
biological activity in the body, the process of glucuronidation is regarded as an 
essential part of detoxification; responsible for the elimination of one-tenth of all 
drugs 3. As an example for emphasizing their necessity, genetic mutation of UGT1A1 
isoform results in jaundice, a disease caused by increased levels of bilirubin in blood 
4.  
1.2 UGT Superfamily 
In mammals, there are two UGT subfamilies that belong to UGT Superfamily: 
UGT1A, located on chromosome 2q37 5 and UGT2, found on chromosome 4q13 6. 
There are 50% sequence similarity among the proteins encoded by these two families 
while the similarity in enzymes belonging to each family reaches up to 60% 7. 
Human UGT1A locus contains 9 functional genes, spanning a region of 200kb 
(Figure 1.1). Each gene has a variable Exon 1 while sharing the remaining four 
exons, Exons 2-5 8. These variable exons are positioned tandemly in the genome and 
are followed by the common exons.  
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mammalian central nervous system, which is a quite sophisticated network, may 
require such a genomic organization to be differentially expressed in a cell and 
developmental-stage specific manner.  
Zhang et al. (2004)14 has conducted a genome-wide research for the determination of 
gene clusters with similar genomic organization, bringing up UDP 
glucuronosyltransferases (UGT1), plectin, neuronal nitric oxide synthase (NOS1), 
and glucocorticoid receptor (GR) gene clusters with more than 10 alternative exons.  
In UGT1A gene cluster, each variable exon shares common motifs in their coding 
areas 15 while regulatory regions at 5’end diverge from each other. Accordingly, 
Tukey and Strassburg (2000)16 has proposed that formation of functional UGT1A 
isoforms requires the binding of RNA Polymerase II to the corresponding promoter 
regions located at 5’flanking sequence of each variable Exon I. Then, each Exon I is 
independently spliced into the upcoming constant exon, generating a distinct UGT1A 
isoform. Indeed, Zhang et al. has shown the presence of CpG islands at 5’ends of 
each exon 14. 
According to this, Zhang et al. (2004)14 speculates that alternating promoters of 
individual Exon 1 of UGT1A1 isoforms make the generation of divergent isoforms 
possible. In addition, independent promoter activation of each exon enables the cell 
to respond to different environmental and homeostatic stimuli. Moreover, each Exon 
1, having a distinct regulatory region, may change the stability of the corresponding 
mRNA and affect its posttranscriptional modifications 14. 
1.4 Conservation of UGT Superfamily among Species 
To what extent the UGT genes are conserved is very well identified in a study by 
Zhang et al. (2004)14. A sequence analysis via VISTA shows that both the variable 
and common exons are highly conserved among human, mouse and rat UGT gene 
clusters 14. Nevertheless, no conservation of intergenic sequences could be observed, 
except the unique intronic region between Exon 1 and 2.  
4 
 
What is also conserved between mouse, human and rat is the unique genomic 
organization of the cluster. However, the number of the variable exons shows 
difference between the species.  
The coding common exons of human UGT1 isoforms show 90% amino acid 
sequence similarity between three species, in addition to full similarity in length of 
the exons 14.  
The classification of variable exons as bilirubin type and phenol type is also 
conserved in rat. In human, bilirubin type exons show an approximately 69% amino 
acid similarity while the sequence identity of amino acids is 73% in the phenol type 
exons 14.  
In case of human UGT1A cluster, bilirubin type and phenol type exons appear to 
have duplicated from two variable exons. In addition, these ancestral exons are 
expected to have duplicated from the one common exon 14. 
There is an extensive study focusing on Ugt superfamily in zebrafish 17. This study 
showed that there are three subfamilies in this species; namely, Ugt1, Ugt2 and Ugt5.  
Ugt1 and Ugt2 clusters have the same genomic organization as their counterparts in 
human: Each variable Exon 1 is independently conjugated with constant exons. 
Phylogenetic comparisons in report of Huang and Wu (2010)17 proposed that the 
ancestral Ugt1 and Ugt2 clusters have gone through a lineage-specific gene loss and 
duplication events resulting in “zebrafish” specific isozymes. 
Ugt5 subfamily, on the other hand, is a novel subfamily appearing specifically in 
teleosts and amphibians. This novel cluster is thought to have formed by 
retrotransposition preceding gene duplication 17.  
1.5 Tissue Specific Expression 
As the main resort of detoxification in the body, UGTs are mainly expressed in liver 
2,18. Nevertheless, there are certain UGT isoforms (UGT1A7, 1A8, 1A10) whose 
expression could only be detected in human gastrointestinal and kidney tissues as 
they contribute to drug metabolism, as well 19. 
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In addition, Nakamura et al. (2008)20 has precisely identified mRNA expression of 
UGT isoforms in human lung, bladder and steroid-related tissues in an isoform-
specific manner. In addition, the same study has demonstrated the isoformic 
expression in certain human cancer cell lines, showing unexpected overexpression or 
suppression. Consequently, each isoform will be discussed in terms of expression 
independently, as follows:  
1.5.1 UGT1A1 
Formerly, UGT1A1 isoform was detected to be expressed in liver in high amounts 21. 
In addition, it was determined that it is expressed in other gastrointestinal organs; 
namely, bile ducts, small intestine, stomach and colon as well as kidney and testis 
20,22-23. 
Nakamura et al. (2008)20  has conducted a study where various human cancer cell 
lines were analyzed in terms of expression of the UGT1A isoforms.  This study has 
additionally showed that 1A1 isoform was expressed in human liver cancer cell lines 
HepG2 and Huh7, and human colon cancer cell lines, Caco-2 and LS180, in high 
quantities. UGT1A1 expression was low in the human kidney cancer cell line HK-2. 
Particularly interesting was that high amounts of UGT1A1 mRNA was detected also 
in human breast cancer cell line MCF-7, and human ovary cancer cell line OMC-3. 
In addition,  1A1 expression was present in low amounts in human breast cancer cell 
line MDA-MB-435, ovary carcinoma cell line, and human adrenocortical carcinoma 
cell line H295R even though it is not expressed in the normal adrenal gland tissue, or 
breast and ovary 20. 
 1.5.2 UGT1A3 
The expression pattern of UGT1A3 is quite similar to that of UGT1A1 isoform. Both 
are expressed in detoxifying organs; such as, liver, small intestine, colon, bile ducts, 
stomach and bladder 8,24-25. Moreover, UGT1A3 was detected in the same cancer 
tissues as in UGT1A1 20. Nevertheless, expression of UGT1A3 is relatively lower, 
implying the possibility that UGT1A1 can compensate for UGT1A3.   
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1.5.3 UGT1A4 
UGT1A4 is an isoform, expressed highly in many tissues. It is a hepatic isoform 
besides being expressed in colon and bile ducts 21,23.  In addition, Kaivosaari et al. 
(2007) 26 encountered its slight expression in trachea, kidney and small intestine. 
Nakamura then added bladder and ovary into this list, as well 20. 
In case of cancer cells, UGT1A4 also shows a similar expression to that of UGT1A1 
20. 
1.5.4 UGT1A5 
This unique isoform is different from all others in that its expression could not be 
detected in most of the tissues for a long time 21,27. Then, in 2002, Collier et al.)28 has 
detected the mRNA transcripts of UGT1A5 in placenta. Afterwards, in 2005 Finel et 
al.29 has proved the presence of a high interindividual variability as in the case of 
UGT1A1, causing a discrepancy in the results. Moreover, Nakamura et al (2008)20 
has shown its presence in gastrointestinal tract, kidney, bladder, and uterus and 
UGT1A5 was marginally detected in the other tissues, as well 20. However, it is 
important to note that it is not expressed in liver.  
When it comes the carcinoma tissues analyzed in Nakamura’s study20, UGT1A5 was 
highly expressed in colon cancer cell line LS180, breast cancer cell lines MDA-MB-
435 and MCF-7, and ovarian cancer cell line OMC-3 20. 
1.5.5 UGT1A6 
mRNA transcript of UGT1A6 isoform was detected in most of the detoxifying 
tissues analyzed. The normal tissues in which UGT1A6 is expressed can be given as: 
liver, stomach, biliary tissue, small intestine, colon, kidney and bladder 24,30. 
In addition, UGT1A6 expression was found in liver cancer cell lines HepG2 and 
HuH7, renal carcinoma cell line HK-2, colon cancer cells Caco-2 and LS180 20. 
Furthermore, lung carcinoma cell line A549 has constitutive UGT1A6 expression 31. 
Interestingly, even though UGT1A6 is not expressed in normal steroid-related 
tissues, it is found in the carcinoma cell lines related with those tissues, such as, 
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adrenal carcinoma cell line H295R, breast carcinoma cell line MCF-7, uterus cancer 
cell line HeLa, adrenal gland carcinoma cell line Ishikawa, and ovarian cancer cell 
line OMC-3 20. This deregulated expression can stem from the fact that UGT1A6 
expression is regulated by hormones and ligands activating pregnane X receptor 
(PXR) and constitutive androstone receptor (CAR) 31-32. 
1.5.6 UGT1A7 
The expression of UGT1A7 isoform can be defined as extrahepatic. In more detail, 
UGT1A7 was identified in esophagus 27 and stomach 22. 
In addition, it is stated that UGT1A7 is not expressed in colon in the reports of 
Strassburg et al. (1999) 27. Nakamura et al.(2008)20, on the other hand, additionally 
detected the presence UGT1A7 isoform in colon as well as small intestine, kidney 
and bladder 20. 
The cancer cells in which UGT1A7 expression was observed are as follows: liver 
cancer cell line HuH7, renal carcinoma cell line HK-2, colon cancer cells Caco-2 and 
LS180, breast carcinoma cell line MCF-7, ovarian cancer cell line OMC-3 20.  
1.5.7 UGT1A8 
UGT1A8 is again an extrahepatic isoform 16,33 but it is expressed in the small 
intestine, colon, kidney, bladder and trachea 20,34. Its expression was found in 
jejunum and ileum, as well 33. Additionally, it was identified in esophagus 27. 
Moreover, the cancer cells showing high expression of UGT1A8 are LS180, H295R, 
MDA-MB-435, MCF-7, and OMC-3 cells 20. 
1.5.8 UGT1A9 
Even though UGT1A9 belongs to the group of phenol-type UGT1A isoforms, 
members of which are not expressed in liver, this isoform shows a high expression in 
liver 10. In addition, colon is a tissue with UGT1A9 expression 21. Additionally, it is 
expressed in esophagus 27. However, where UGT1A9 abundantly expressed besides 
liver is kidney 35. Expectedly, the carcinoma cell line with UGT1A9 expression is 
Hk-2 cells, derived from kidney 20. 
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Ohno and Nakajin (2009)34claim that mRNA of UGT1A9 is also present in adrenal 
glands, small intestine, and colon; while Nakamura et al. (2008)20 adds to this list, 
bladder and testes 20,34. 
1.5.9 UGT1A10 
Initially, UGT1A10 isoform was identified in certain members of gastrointestinal 
tract; such as, stomach, intestine and colon, in addition in biliary epithelium, but not 
in liver 21,36-37.  Then, it also was found in esophagus 27.  
The expression of UGT1A10 was recently found in liver, kidney, ovary, and uterus 
even though it is extremely low 20. 
UGT1A10 was found to be highly expressed in LS180 and MCF-7 cells, in addition 
to H295R, MDAMB-435, HuH7, and OMC-3 cells 20. 
1.6 Nicotine  
Nicotine is a pyridine alkaloid. When administered, it increases the dopamine levels 
in the brain, triggering an addiction 38. Possessing this ability, it is defined as the 
addictive compound in cigarettes.   
Nicotine is absorbed from the alveoli of lungs very rapidly and at the cessation of 
smoking, the blood concentrations of nicotine reaches to its highest level 39-40. Total 
nicotine clearance from body takes approximately 2 hours. 
1.7 Nicotine Metabolism  
Nicotine removal from body is mainly carried out in liver by the enzymes, CYP2A6, 
UDP-glucuronosyltransferases (UGT), and flavin-containing monooxygenase 3 
(FMO3) 38.  
In mammals, most of nicotine (approximately 75%) is metabolized to cotinine by the 
action of CYP2A6. Moreover, cotinine is further metabolized to trans-3′-
hydroxycotinine (3HC) and less-harmful side-products again by the oxidation 
reactions catalyzed by CYP2A6 enzymes 41. 
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Additionally, nicotine is metabolized by UGT enzymes, which constitutes 3-5% of 
nicotine metabolism. This reaction generates an N-quaternary glucuronide and 
enables its excretion through urinary system. In addition, other major metabolites of 
nicotine, which are cotinine and trans-3′-hydroxycotinine (3HC), are subjected to 
glucuronidation by UGTs, as well. Overall, 31% of all nicotine metabolites found in 
urine are composed of phase II glucuronidated compounds depending on the activity 
of ER-resident UGT enzymes 42. Eventually, the glucuronidated nicotine metabolites 
are removed from the body by urinary system. 8-10% of nicotine administered 
remains as unchanged and excreted in urine, as well. 
Among the UGT1A isoforms, a potential role for the isoforms UGT1A4 and 1A9 has 
been suggesting for the glucuronidation of nicotine and its abundant metabolite, 
Cotinine in vitro 43.   
1.8 Real-Time PCR Analysis  
Each gene has its own unique pattern of expression, varying from cell to cell or as a 
response to differing physiological conditions 44. It is of importance to analyze the 
gene expressions in molecular biology; for example, when assessing the response of 
cells to external/internal stimuli, to different developmental stages or for diagnostic 
purposes 44. 
Reverse Transcription of whole cellular mRNA content, followed by PCR has been a 
robust and reliable technique for gene expression analyses since 1993 45. In addition, 
the advent of Real-Time PCR enhanced this protocol and enabled collection of data 
during amplification by means of fluorescence emission 46. 
PCR reaction can be divided into four distinct stages 47-48. Firstly, linear ground stage 
takes place in which PCR starts and fluorescence emission is not high enough to be 
detected. This is followed by the stage at which exponential amplification takes place 
and fluorescence emission exceeds a certain threshold cycle (also known as Ct). The 
threshold cycle enables us to determine the amount of starting DNA template since 
the more the template, the sooner the Ct is reached 49. The third stage is when log-
linear amplification of the products occurs and a steep increase in fluorescence is 
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observed. Eventually, reaction components become scarce, exponential accumulation 
of the products cease and a plateau phase is reached. 
In order to collect data during amplification, there are two well-established methods 
used, i.e., gene-specific probes and double strand-binding agents 50. Probe-based 
systems rely on the 5’-3’ nuclease activity of Taq polymerase and after they 
recognize and bind their target on the single strand, polymerase causes their 
hydrolysis during elongation and a consequent fluorescence emission 46.  
DNA binding dyes are used based on their ability to emit fluorescence when they 
intercalate with double strand DNA. As the amplicons accumulate, fluorescence 
intensity is increased proportionally 51. Generally, SYBR Green or Ethidium 
Bromide is preferred for this purpose 52. In cases when sequence specific, intron-
spanning primer couples are used, SYBR Green has been shown to work quite 
efficiently 45. However, since these dyes fail to specifically recognize the target 
amplicons, the false positive rate might be high 53. In order to prevent this, PCR 
products should be run on gel 54 and dissociation curves should be checked whether 
there are unrelated melting peaks 55. 
Real-time PCR data can be given in several reporting methods, including absolute 
quantification and relative quantification. Absolute quantification reports the results 
by relating Ct values with input copy number linearly via a calibration curve. The 
calibration curves are plotted using known concentrations of DNA, e.g., recombinant 
DNA, genomic DNA or RT-PCR product 56. This method is based on the assumption 
that all standards and samples bear approximately equal efficiencies 57.  
Relative quantification, on the other hand, as the name implies, presents the gene 
expression levels relative to an internal standard 58. The internal references are 
generally house-keeping/reference genes, which show steady-state expression in all 
samples 45. There are numerous mathematical methods designed to assess the relative 
expression of genes to an endogenous reference. An established mathematical model 
is presented in the paper of Pfaffl et al. (2001)59. This method calculates the gene 
expressions as a relative fold change between target genes and reference, including 
the efficiency values of each primer. The fold change is calculated as follows: 
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Fold change = (Etarget) ΔCtTarget (control-sample)/ (Ereference) ΔCtReference (control-sample) 
Here, the formula assumes that Ct value of the reference gene does not show 
deviation among control and sample; thus, ΔCtReference is set as 0. The formula 
requires an efficiency value for each primer couple together with the enzyme used. 
Ideally, the amplification efficiency in each reaction is assumed to be 1, implying 
that the amplicon concentration doubles itself in each cycle at log phase 60. 
Nevertheless, in actuality, every reaction has its own efficiency value and the failure 
in calculating that may overestimate the results 61.  
In order to calculate the efficiency of the primers, a widely used formula is as 
follows: 
E=Magnitude of dilution [-1/slope of the dilution curve] 
The slopes are derived from the calibration curve that is plotted against serially 
diluted samples and the corresponding Ct values run with the same enzyme and 
primer couple. Eventually, the statistical significance of the results should be 
determined by standard parametric tests; such as ANOVA and t-tests 62. 
1.9 SW620 Colon Adenocarcinoma Cell Line as a Model System 
SW620 colon adenocarcinoma cell line is a metastatic form of a primary 
adenocarcinoma cell line SW480, which was initially isolated from a 51-year old 
Caucasian male 63. Within a year, a metastasis was observed from the colon to 
abdomens and SW620 cell line was isolated from a lymph node. SW620 cells were 
shown to be highly tumorigenic when injected to nude mice 64. 
This cell line is a good model for studying UGT1A expression since colon is the 
second organ where UGTs are expressed most. In addition, there is a study 
displaying that Pregnane X Receptor (PXR), a UGT1A expression regulator, 
responds to the drug irinotecan in SW620 cells 65. Irinotecan is a widely used drug in 
treatments of colon cancer. When SW620 cells are treated with irinotecan, the 
expression of PXR as well as UGT1A1, UGT1A9 and UGT1A10 are upregulated. 
Thus, SW620 establishes a good model for analyzing the effect of nicotine on colon 
cancer cells in terms of UGT1A expression.
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2. AIM OF THE STUDY 
Chemical defense pathways are evolved to protect cells from toxic xenobiotics. It is 
especially of critical importance in organs exposed to xenobiotics most. There are 
two detoxification routes for biochemical modification of the compounds, namely, 
phase I drug metabolism involving oxidation/reduction and hydrolysis reactions and 
phase II drug metabolism indicating conjugation 2. Glucuronidation, as a phase II 
drug metabolic pathway, is responsible for conjugating glucuronic acid to its 
numerous lipophilic substrates, converting them into hydrophilic molecules. In cell, 
glucuronidation is predominantly catalyzed by a family of UDP-glucosyltransferases 
(UGTs) 2,66-68. UGTs take a central role in elimination of one tenth of all drugs 3. 
That’s why it is important to understand how their expression changes in response to 
which drug. 
Each year, over 1 million people are expected to develop colorectal cancer 69. In 
addition to genetic factors, the life style of the individual affects the possibility of the 
advent of the disease 70. Colon acts as the primary barrier that initially and directly 
contacts with the any toxic and carcinogenic compound that we are daily exposed to 
in our lives (by smoking, food, medication, etc.). That’s why; colonic cells should 
bear effective defense pathways against them, including glucuronidation. 
Liver is classified as the main resort for the elimination of toxic substances in the 
body, originating either endo- or exogenously 2,18. Nevertheless, the metabolism of a 
drug, when administered orally, starts at the epithelial cells of the gastrointestinal 
(GI) tract, which is called first-pass metabolism 71. The epithelial cells lining the GI 
tract possess their own metabolic pathways and start the metabolizing reactions 
during absorption of the chemical. Among the organs, contributing both to 
absorption and detoxification of the drugs are skin, intestine, oral and nasal 
epithelium, as well as lung and kidney 72. When the compound reaches to liver, its 
extensive metabolism begins and then, it joins to systemic circulation of the body so 
that it can exert its biological activity on target tissue. 
In mammals, there are two subfamilies of UGT Superfamily, each located on a 
different chromosome. In this study, however, we focused on merely the expression 
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of UGT1A family since these enzymes are primarily involved in the metabolism of 
xenobiotics while UGT2 family is mostly responsible for the metabolism of 
endogenous compounds 70. 
UGT genes are mainly expressed in liver in an isoform-specific manner 20. It is 
documented that 1A1, 1A3, 1A4, 1A6, 1A9 are the isoforms expressed abundantly in 
liver, taking roles in hepatic drug metabolism 3,73. However, there are studies 
showing that the other detoxifying organs with a different profile of UGT isoform 
expression can well catalyze glucuronidation of numerous drugs 74. To be more 
precise, UGT1A1, and UGT1A10 are expressed highly in intestine 34 while the 
primary tissues expressing 1A7 and 1A8 are members of GI tract 20. Kidney is the 
organ where UGT1A9 is expressed at most 34. 
Nicotine is one of the most effective addictive compounds in tobacco 75. There have 
been numerous research studies ongoing regarding to effects of nicotine on cells.  So 
far, it has been known that nicotine promotes the proliferation of tumor cells in vivo; 
however, a study showing that nicotine causes transformation of normal cells into 
tumor cells is absent 76. 
Smoking has been related with many diseases, such as cardiovascular diseases as 
well as cancer. Smoking has been associated with UGT1A expression via changes in 
transcription factors 77. According to this study, smoking upregulates an oxidative 
stress response transcription factor Nrf2 and UGT1A4 and UGT1A6 are coordinately 
expressed with this regulator in small airway epithelia. This initial report initiated us 
to look at a more generalized set of microarray datasets that contain information on 
smoker and non-smokers to generalize the previous findings. 
Tobacco smoke contains a multitude of chemicals one of which is nicotine. Nicotine 
is the addictive component in tobacco; and has additionally been associated with 
lung cancer previously. Nevertheless, the crosstalk between nicotine and colon 
cancer cells, especially SW620 cells, has not been elucidated in detail. Our previous 
studies showed that nicotine upregulates proliferation in SW620 cells when serum 
starved 78. Kaya (2009)78 has shown that nicotine increases survival of SW620 cells 
and a plethora of mRNA transcripts identified by microarrays were involved in this 
effect. Among the transcripts that are responsive to nicotine but not serum 
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replenishment are the probesets that belong to UGT1A isoforms. This prompted the 
present study for identification of isoform expression of UGT1A in SW620 cells 
under serum starvation. 
The present thesis thus has the rationale of revealing the connection between UDP-
glucuronosyltransferases with smoking in vivo and with nicotine in SW620 colon 
adenocarcinoma cells. The methods used for accomplishing these aims included 
microarray expression analysis of publically available datasets obtained from GEO 
and qRT-PCR studies of UGT1A isoforms using primers published in Nakamura et 
al. (2008) 20. 
For this purpose, there are certain questions that we build our experiments on as 
shown below: 
- Does smoking upregulate UGT1A expression in vivo? 
- What are potential reference genes for studying effects of nicotine on gene 
expression? 
- Is there a change in expression of genes related with cell proliferation when SW620 
cells are administered with 1µM Nicotine for 48h? 
- Does 1µM Nicotine treatment for 48h upregulate UGT1A isoform expression when 
cells are grown under physiological serum levels (10%) or serum starved (0.1%)? 
-Could there be a relationship between sequence and expression of UGT1A genes?
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3. MATERIALS AND METHODS 
3.1 Cell Line 
The cell line of interest, SW620 colon adenocarcinoma cell line, is supplied by 
American Type Culture Collection (ATCC; Manassas, USA) with an ATCC number 
of CCL-227. SW620 colon adenocarcinoma cells are derived from a 51 years-old 
male and are metastatic.  This cell line is kindly presented by Assist. Prof. Dr. 
Sreeparna Banerjee, METU, Ankara.  
3.2 Cell Preservation Protocols 
The base medium for SW620 colon adenocarcinoma cells is formulated as DMEM 
(FG0415) (Biochrom AG, Berlin, Germany); added with 10% Fetal Bovine Serum 
(CH30160) (Hyclone, Logan, USA) and 1% Penicillin/Streptomycin mixture 
(SV30010) (Hyclone, Logan, USA).  
Cells are grown as supplemented with 12-14mL of complete media in 75-T flasks 
(Greiner Bio One, Frickenhausen, Germany) in the 37oC incubator with 5% CO2. In 
three days interval, cells are passaged into new flasks as described in Kaya (2009) 78.  
For cryopreservation, cells were detached with trypsinization and centrifuged. The 
pellet, then, is resuspended in freezing media (i.e., complete media supplemented 
with 5% (v/v) DMSO; Sigma-Aldrich, St. Louis, MO, U.S.A) and kept in liquid 
nitrogen tanks for long time storage. Cell culturing experiments for SW620 cells 
were performed by Onur Kaya 78. 
3.3 Nicotine and Serum Starvation Treatment 
To see the effects of nicotine treatment in cells grown in either complete media or 
serum deprived media, 1x106 SW620 cells were seeded onto 75-T flasks. After 24h, 
in which cells attach on the surface, media were replaced with serum starved media 
(prepared as supplementing DMEM with 0.1%FBS and 1%Penicillin/Streptomycin 
solution) for induction of quiescence. 
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Quiescent cells were transferred to complete media with different concentrations of 
nicotine; namely, 10ηM, 100ηM, 1μM and 10μM for 48 hours 78.  
Alternatively, another set of a condition was prepared by growing the cells either 
with complete media, complete media containing 1μM Nicotine, serum-deprived 
media (0.1%FBS containing media) or serum-deprived media including 1μM 
nicotine for 48 hours. Each condition was designed so that there are biological 
replicas. Nicotine and serum starvation treatments were performed by Onur Kaya 78. 
3.4 Total RNA Isolation 
Treated cells were collected from the flasks on the 2nd day of the treatments by cell 
scraper as dissolved in ice-cold 1X PBS solution. Following, cells were centrifuged 
at 1500rpm for 5 min at 4°C and the pellets are stored at -80°C till RNA isolation 78.  
Total RNA isolation is carried out with Promega SV Total RNA isolation kit (Z3100) 
(Madison, USA) according to the manufacturer’s protocol. The RNA concentration 
was measured by NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, 
Wilmington, DE, USA). Total RNA was used for microarray analysis and cDNA 
synthesis. The integrity of the RNA samples for microarray analysis was assessed by 
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). RNA 
isolation and quality controls were performed by Onur Kaya 78. 
3.5 SW620 Nicotine Treatment Microarray Experiment 
5μg RNA samples were hybridized with Affymetrix U133 plus 2 GeneChips 78. 
Amplification, labeling and hybridizations were performed at the Genomics Core 
Facility of Bilkent University by the facility technician under the supervision of Assoc. 
Prof. Dr. Işık Yuluğ according to manufacturer’s protocols.  
3.6 Microarray Analysis Methods 
BRB array tools has been chosen for data analysis of microarray results 79. Each .cel 
file was imported to Microsoft Office Excel as a BRB Project. During import of data, 
no specific filtering criteria were employed.  
Normalization: 
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Normalization was carried out by justRMA Normalization option integrated in BRB-
Array tools. No preferences or filters were used for normalization to be able to see 
whole data and see the big picture. 
Class Comparison: 
In order to set a table of differentially expressed genes versus corresponding 
intensities, unpaired-class comparison tool of BRB Array tools with a p-value of 0.05 
was used. After annotating each array as either smoker or non-smoker, differentially 
expressed genes were explored by Class Comparison among these two groups. BRB-
array tools make use of univariate parametric tests (t/F) to define differentially 
expressed genes among two groups. Class comparison analyses also provide a false 
discovery rate value (FDR). This allows multiple test correction for the probesets 
analyzed from microarray analyses. 
Cluster and Treeview: 
Clustering was carried out by Cluster 3.0 software program while the image was 
generated by Java TreeView software 80. For this purpose, differentially expressed 
genes among all the groups derived from unpaired-class comparison tool of BRB 
Array tools (with a P-value of 0.05) were uploaded on Cluster 3.0. Then, median 
gene and array centering was performed. Average linkage method was chosen and 
un-centered correlation coefficient was used.  
3.7  Re-analysis of Public Datasets for UGT1A probesets 
Publicly available datasets were gathered by searching through Gene Expression 
Omnibus (GEO) website and using “Smoke or smoking or Nicotine” as keywords81. 
In order to analyze as many datasets as possible, Affymetrix HG-U133A, HG-U133 
plus 2 and HuGeneFL Human Full Length Arrays were collected. 
According to Ensembl database, there are five probesets in Affymetrix HG-U133A 
and HG-U133 Plus 2 arrays that give hits on all UGT1A isoforms. These probesets 
are: 
 204532_x_at 
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 206094_x_at 
 207126_x_at 
 208596_s_at 
 215125_s_at 
In addition, there is extra probeset in the same arrays matching with UGT1A8 and 
UGT1A9 genes. This probeset is 221305_s_at. 
Also, there is a probeset that is assigned only to UGT1A6 isoform in addition to 
those given above; which is 232654_s_at. However, this probeset is present only in 
Affymetrix HG-133 plus 2 arrays. 
Furthermore, in HuGeneFL Human Full Length array, there is only one probeset that 
recognizes all UGT1A isoforms; namely, J04093_s_at. 
We have analyzed several microarray results obtained in [HG-U133_Plus_2] 
Affymetrix Human Genome U133 Plus 2.0 Array, [HG-U133A] Affymetrix Human 
Genome U133A Array or [Hu6800] Affymetrix Human Full Length HuGeneFL 
Array Table 5.1, Table 5.2, Table 5.3 and Table 5.4. To do so, we have used BRB-
Array Tools as described above in Section 3.6. We have normalized the .cel data 
downloaded from the webpage of each array in GEO database with justRMA option 
of BRB Array tools. Each array was annotated as either smoker or non-smoker and a 
class comparison was done between these two groups as setting p value as 0.05. The 
results of each re-analysis were shown below labeled with GSE numbers and short 
explanation of the clinical sample. 
3.8 Statistical Analysis and Plots of GEO Expression Values using GraphPad 
Initially, the normalized values for each probeset in a dataset were obtained as non-
log values. The geometric mean and standard deviation of each group were 
calculated and uploaded to GraphPad (GraphPad Software, Inc.). This program plots 
bar graphs according to the mean and SD given. The statistical significance of 
alteration in probesets was assessed depending on the p-value and FDR-value 
determined by BRB-Array tools. 
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3.9 cDNA synthesis 
cDNA synthesis was done with RevertAid First Strand cDNA synthesis kit (K1622) 
(MBI Fermentas, Ontario, Canada) according to manufacturers’ protocol. 
3.10 Validation of Microarray Analysis with qRT-PCR 
For quantitative Real-time PCR experiments, Maxima SYBR Green qPCR Master 
Mix (K0251) obtained from MBI Fermantas (Ontario, Canada) was used with 
Applied Biosystems 7500 Real-time PCR systems (California, USA). 
3.10.1 Oligonucleotides:  
The oligonucleotides for qRT-PCR analysis of UGT1A isoforms were adapted from 
the study of Nakamura et al. (2008) 20 for comparability. They were synthesized by 
Iontek Inc. (Istanbul, Turkey). For all UGT1A primer couples, same reverse primer 
was used. Oligonucleotides to check for the proliferative capacity of SW620 cells 
treated with nicotine also were ordered from Iontek Inc. (Istanbul, Turkey).  The 
oligo sequences of the primers, their expected amplicon size and annealing 
temperatures are shown on Table 3. 1,  
,Table 3. and Table 3.3.  
Table 3. 1 The oligonucleotides used for UGT1A expression analysis. Adapted from 
Nakamura et al. (2008) 20.    
Gene name Forward Primer  Reverse Primer Amplicon 
size 
Annealing 
Temp 
UGT1A1 5’CCT TGC CTC AGA 
ATT CCT TC 3’ 
5’ ATT GAT CCC AAA 
GAG AAA ACC AC 3’ 
361bp 58°C 
UGT1A3 5’GTT GAA CAA TAT 
GTC TTT GGT CT 3’ 
5’ ATT GAT CCC AAA 
GAG AAA ACC AC 3’ 
595bp 58°C 
UGT1A4 5’CCT GCT GTG TTT 
TTT TGG AGG T 3’ 
5’ ATT GAT CCC AAA 
GAG AAA ACC AC 3’ 
431bp 58°C 
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UGT1A5 5’TGT CCT ACC TTT 
GCC ATG CTG 3’ 
5’ ATT GAT CCC AAA 
GAG AAA ACC AC 3’ 
274bp 58°C 
UGT1A6 5’CAA CTG TAA GAA 
GAG GAA AGA C 3’ 
5’ ATT GAT CCC AAA 
GAG AAA ACC AC 3’ 
97bp 58°C 
UGT1A7 5’CCC CTA TTT TTT 
CAA AAA TGTCTT 3’ 
5’ ATT GAT CCC AAA 
GAG AAA ACC AC 3’ 
261bp 58°C 
UGT1A8 5’GGT CTT CGC CAG 
GGG AATAG 3’ 
5’ ATT GAT CCC AAA 
GAG AAA ACC AC 3’ 
423bp 58°C 
UGT1A9 5’GAA CAT TTA TTA 
TGC CAC CG 3’ 
5’ ATT GAT CCC AAA 
GAG AAA ACC AC 3’ 
275bp 58°C 
UGT1A10 5’CTC TTT CCT ATG 
TCC CCA ATG A 3’ 
5’ ATT GAT CCC AAA 
GAG AAA ACC AC 3’ 
364bp 58°C 
 
,Table 3.2 The oligonucleotides used as reference genes in SW620 cells. 
Gene name Forward Primer  Reverse Primer Amplicon 
size 
Annealing 
Temp 
RPL3 5’ CCT TCT CTG TGG 
CAC GCG CT  3’ 
5’ CCG CTT CGT CTG CAC 
CAG CA 3’ 
284bp 60°C 
RPL10 5’ ACC TGG GGC GGA 
AAA AGG CA  3’ 
5’ GGT GGA GCC GCA 
CCC GGA TA 3’ 
174bp 60°C 
GAPDH 5’GGC TGA GAA CGG 
GAA GCT TGT CAT 3’ 
5’ CAG CCT TCT CCA TGG 
TGG TGA AGA 3’ 
142bp 60°C 
PPIA 5’ CGT GTG CTA TTA 
GCC ATG GT 3’ 
5’  CAT TAT GGC GTG 
TGA AGT C 3’ 
229bp 60°C 
RPLP0 5’TCATCCAGCAGGT
GTTCGAC C 3’ 
5’ AGA CAA GGC CAG 
GAC TCG TT 3’ 
194bp 60°C 
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Table 3.3 The oligonucleotides used for the analysis of proliferative capacity in 
SW620 cells. 
Gene name Forward Primer  Reverse Primer Amplicon 
size 
Annealing 
Temp 
ANLN 5’ TAA AGC AGG TGA 
TTG TTC GG  3’ 
5’ GTT CTT CAT CAA CAC 
AGC AG  3’ 
180bp 60°C 
MKI67 5’ GTG TCA AGA GGT 
GTG CAG AA  3’ 
5’ GCC TTA CTT ACA GAA 
TTC AC  3’ 
197bp 60°C 
 
3.10.2 Quantitative Real-time PCR 
The primer pairs targeting the genes in interest to analyze the change in their 
expression as a response to nicotine and serum starvation treatments are given in 
Table 3.1, 3.2 and 3.3.  For each reaction, 12.5 μl 2X SBYR Green Master Mix (MBI 
Fermantas, Ontario, Canada) was added with 0.75 μl 10pmol/ μl forward and reverse 
primers, 0.05µl 10nM ROX solution as a reference dye and total volume was 
completed to 24 μl with distilled water. Reaction volume was completed to a total of 
25 μl with 1:2 diluted cDNA templates. The reaction was as follows: initial 
denaturation at 95ºC for 10 min, followed with 40 cycles of 30s of 95 ºC, 30s of 58 
ºC, 30s of 72 ºC and final extension at 72 ºC for 10 min.  Dose-dependent nicotine 
samples grown at 10%FBS were run with two technical duplicates while serum 
starved samples were run with three biological replicates and two technical 
duplicates. 
Melting curves and Ct values were automatically obtained from the software of 
Applied Biosystems 7500 Real-time PCR systems (California, USA). Each melting 
curve was analyzed to see whether negative controls were free of product and 
samples resulted in a single amplicon. For each primer pair, an efficiency value was 
calculated by running a reaction with 2-fold serially diluted cDNA and formula as 
shown below:  
E=2 [-1/slope of the dilution curve] 
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Fold changes in gene expression was calculated by normalizing according to the 
expression of a reference gene, i.e., GAPDH. GAPDH was chosen among five 
potential reference genes, as one of the most stable ones across nicotine treatment  
,Table 3.. The mathematical formula used for determination of fold changes was 59: 
(Etarget) ΔCtTarget (control-sample)/ (Ereference) ΔCtReference (control-sample) 
Following the runs, each PCR product was run on 2% Agarose Gel Electrophoresis. 
3.10.3 ANOVA Analysis of UGT1A isoforms from qRT-PCR 
The fold changes normalized to GAPDH levels of each control and treated samples 
were uploaded to Minitab Statistical Software 82 and One-way ANOVA (Unstacked) 
option was used to calculate DF, F-value and p-value.  
3.11 General Solution Recipes 
10X PBS Stock solution: 80g NaCl, 2g KCl, 11.5g Na2HPO4.7H2O, and 2g 
KH2PO4 are weighed and dissolved in ddH2O to a total volume of 1 liter and 
autoclave steriled. 
1X PBS Working solution: 10X PBS was diluted with 1:10 ratio and pH is adjusted 
to 7.4. Working solution should be autoclaved for one more time after dilution and 
filtered before use in tissue culture.   
50X Tris-acetic acid-EDTA (TAE): 242gr Tris Base and 18.6g EDTA are dissolved in 
ddH2O. They are added with 57.1mL Glacial Acetic acid and volume is completed to 1 
liter.  
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4. RESULTS 
4.1 Re-analysis Microarray Datasets with Smoker Status from GEO 
In order to answer the question whether smoking induces the expression of UGT1A 
genes in vivo, we performed a large-scale re-analysis of publicly available datasets 
that contain information on past and/or smoking status.  
As given in Ensembl database, probesets assigned for UGT1A isoforms are uniform, 
implying that they do not differentiate each isoform. The reason is that since RNA 
degradation begins at 5’end, probesets are designed to hit on 3’ends. Because 
UGT1A isoforms share the same common 3’ends, it is not possible to discriminate 
among them using microarray experiments from Affymetrix. Consequently, we can 
only observe the changes in expression of UGT1A isoforms as a whole, and the 
alterations occurring on each gene are not well reflected on the results. In other 
words, an increase in the expression of a certain isoform may cover a decrease in the 
other. Nevertheless, the significant changes in expression can be observed anyway. 
Furthermore, there are specific probesets that additionally recognize the certain 
isoforms UGT1A8 and UGT1A9. In addition, there is a specific probeset hitting on 
UGT1A6 gene only in HG133 Plus 2.0 Array. 
After normalization and class comparison of the data, a list of genes that are 
differentially expressed among smokers and non-smokers was obtained using the 
class comparison tool (p<0.05). Afterwards, the probesets that are annotated for 
UGT1A isoforms in the corresponding chip type were surveyed whether they are 
differentially expressed, as well.  
Below, a short summary of each dataset chosen and the corresponding intensities of 
each UGT1A probeset in that array if significantly expressed (p<0.05) were shown. 
In addition, the geometric mean of probeset intensities was represented with a bar 
graph for each array. 
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GSE4635: Large airway bronchial epithelial cells 
This array was designed to analyze the distinct transcriptomic profiles in large 
airway bronchial epithelial cells, differentiating smokers from non-smokers. There 
were 5 healthy non-smoker and 5 healthy smoker samples, whose RNA were 
hybridized with [HG-U133A] Affymetrix Human Genome U133A Array. Samples 
for RNA were isolated from right mainstem bronchus of individuals by means of 
fiberoptic bronchoscopy 83. Based on the knowledge that, airway epithelium is one of 
the tissues that might be exposed to nicotine most, the findings might implicate to the 
relationship between smoking and UGT1A expression. 
Class comparison tool of BRB-Array tools has brought up 906 genes that are 
significantly changed (p<0.05) among smokers and non-smokers. In this gene list, 
there were probesets annotated to UGT1A isoforms, as well (Table 4.1). According 
to this data, UGT1A expression was significantly upregulated (p<0.05) in airway 
epithelium of smokers by an average of 2 fold change constant as compared to non-
smokers (Figure 4.1). In addition, UGT1A8 and UGT1A9 expression did not change 
among smokers and non-smokers (Figure 4.2). Indeed expression level of these 
probesets was very low making the detection of their differential expression difficult. 
Table 4.1 The geometric mean of intensities corresponding to common UGT1A 
probesets in GSE4635 array (p<0.05). 
Parametric p-
value 
FDR Non-smokers 
(Geom mean of 
intensities) 
Smokers 
(Geom mean 
of intensities) 
Fold-
change 
Probe set 
0.0004475 0.19 217.39 411.29 0.53 204532_x_at 
0.0016715 0.443 214.49 382.03 0.56 206094_x_at 
0.0012313 0.365 225.28 424.74 0.53 207126_x_at 
0.0208181 1 149.26 241.53 0.62 208596_s_at 
4.44E-05 0.0707 99.82 250.35 0.4 215125_s_at 
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Figure 4.1 UGT1A expression in large airway epithelium of smokers and non-
smokers according to GSE4635 array (* p<0.05,**p<0.001).  Results were given as 
geometric mean ± SD. 
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Figure 4.2 UGT1A8-1A9 expression in large airway epithelium of smokers and non-
smokers according to GSE4635 array (* p<0.05,**p<0.001). Results were given as 
geometric mean ± SD. 
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GSE4498: Small airway bronchial epithelial cells 
This dataset is focused on specific arrays originally conducted as a part of superseries 
GSE5060 84.  Overall, GSE5060 superseries aim to analyze how cigarette smoking 
affects neuroendocrine cells in human airway epithelium. Based on this question, 
they have analyzed both large and small airways of phenotypically normal smokers 
and non-smokers, in addition to patients with early COPD and COPD. Since we try 
to assess the effects of smoking on healthy individuals, we excluded the subseries 
analyzing patients with COPD. Moreover, all subseries were not hybridized with the 
same platform. Thus, we decided to analyze each subseries individually.  
GSE4498 is composed of small airway epithelial samples from 10 healthy non-
smokers and 12 healthy smokers obtained via fiberoptic bronchoscopy. The platform 
used is [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array. 
Among 6543 genes with significance of p<0.05, there were common UGT1A 
probesets (Table 4.2) and UGT1A6 (Table 4.3) and UGT 1A8- 1A9 probesets, as well 
(Table 4.4). Accordingly, smokers have at least twice the expression of UGT1A 
isoforms when compared with non-smokers (Figure 4.3) where FDR was less than 
0.05. UGT1A6 probeset detected a very low expression in non-smokers, which again 
was doubled in smokers (Figure 4.4). UGT1A8 and UGT1A9 probesets detected very 
low expression, which was difficult to distinguish from base-line background 
expression (Figure 4.4). 
Table 4.2 The geometric mean of intensities corresponding to common UGT1A 
probesets in small airway bronchial epithelial cells from GSE4498 (p<0.05). 
Parametric p-
value 
FDR Non-smokers 
(Geom mean of 
intensities) 
Smokers (Geom 
mean of 
intensities) 
Fold-
change 
Probe set 
1.00E-07 0.000342 112.2 338.11 0.33 204532_x_at 
5.00E-07 0.0013 121.27 332.65 0.36 206094_x_at 
1.00E-07 0.000342 119.88 354.75 0.34 207126_x_at 
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4.00E-07 0.00109 120.92 416.67 0.29 208596_s_at 
7.30E-06 0.00849 79.82 261.01 0.31 215125_s_at 
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Figure 4.3 UGT1A expression in small airway epithelium of smokers and non-
smokers according to GSE4498 (* p<0.05,**p<0.001). Results were given as 
geometric mean ± SD. 
Table 4.3 The geometric mean of intensities corresponding to UGT1A6 probeset in 
GSE4498 (p<0.05) 
Parametric p-
value 
FDR Non-smokers 
(Geom mean 
of intensities) 
Smokers 
(Geom mean 
of intensities) 
Fold-change Probe set 
0.0025036 0.159 16.76 25.89 0.65 232654_s_at 
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Table 4.4 The geometric mean of intensities corresponding to UGT1A8 and 1A9 
probeset in GSE4498 (p<0.05) 
Parametric p-
value 
FDR Non-smokers 
(Geom mean 
of intensities) 
Smokers 
(Geom mean 
of intensities) 
Fold-
change 
Probe set 
0.0196277 0.328 10.75 11.99 0.9 221305_s_at 
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Figure 4.4 UGT1A6 (232654_s_at), UGT1A8 and 1A9 (221305_s_at) expression in 
small airway epithelium of smokers and non-smokers according to GSE4498 
(*p<0.05, **p<0.001). Results were given as geometric mean ± SD. 
 
GSE10006: Human airway bronchial epithelial cells 
This array is another study concerning the changes at the transcriptomic level in the 
airway epithelium of smokers and non-smokers 85. Nevertheless, the dataset is 
comprised of samples from both healthy and sick individuals. Therefore, we 
excluded the samples from patients with COPD, leaving 58 healthy samples behind.  
With significance of p<0.05, there were 11240 genes that were differentially 
expressed; among which there were UGT1A genes (Table 4.5). Furthermore, 
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probesets annotated for UGT1A6 (Table 4.6) and UGT1A8-1A9 significantly 
changed, as well (Table 4.7). 
Analysis of GSE10006 further showed that human airway epithelial cells bear a 
defense mechanism against smoking. This notion was supported by close to three 
fold upregulation of UGT1A common probesets (Figure 4.5) as well as UGT1A6 
(less than two fold). However, 1A8 and 1A9 specific probes (Figure 4.6) did not 
exhibit differential expression at the level of FDR=0.05; furthermore, the expression 
of UGT1A8 and UGT1A9 was low based on the given microarray probesets.  
Table 4.5 The geometric mean of intensities corresponding to common UGT1A 
probesets in GSE10006 (p<0.05). 
Parametric p-
value 
FDR Non-smokers 
(Geom mean of 
intensities) 
Smokers 
(Geom mean 
of intensities) 
Fold-
change 
Probe set 
< 1e-07 < 1e-07 189.71 505.94 0.37 204532_x_at 
1.00E-07 5.26E-05 172.08 405.18 0.42 206094_x_at 
< 1e-07 < 1e-07 167.94 428.43 0.39 207126_x_at 
1.00E-07 5.26E-05 183.89 537.32 0.34 208596_s_at 
1.00E-07 5.26E-05 130.91 401.78 0.33 215125_s_at 
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Figure 4.5 UGT1A expression in small airway epithelium of smokers and non-
smokers according to GSE10006 (* p<0.05,**p<0.001). Results were given as 
geometric mean ± SD. 
Table 4.6 The geometric mean of intensities corresponding to UGT1A6 probeset in 
GSE10006 (p<0.05) 
Parametric p-
value 
FDR Non-smokers 
(Geom mean of 
intensities) 
Smokers 
(Geom mean of 
intensities) 
Fold-
change 
Probe set 
0.000199 0.014 21.47 31.28 0.69 232654_s_at 
 
Table 4.7 The geometric mean of intensities corresponding to UGT1A8-1A9 
probeset in GSE10006 (p<0.05) 
Parametric p-
value 
FDR Non-smokers 
(Geom mean of 
intensities) 
Smokers 
(Geom mean 
of intensities) 
Fold-
change 
Probe set 
0.0136421 0.141 14.23 17.44 0.82 221305_s_at 
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Figure 4.6  UGT1A6 (232654_s_at), UGT1A8 and 1A9 (221305_s_at) expression in 
airway epithelium of smokers and non-smokers according to GSE10006 (* p<0.05, 
**p<0.001). Results were given as geometric mean ± SD. 
GSE17913: Oral Mucosa 
GSE 17913, an extensive dataset, is of big importance in that it is one of the 
pioneering studies in literature showing that the expression of UGT enzymes was 
regulated by cigarette smoking 86. This study was conducted on 39 healthy smokers 
and 40 healthy non-smokers. The RNA samples belong to oral mucosa of the 
individuals and were obtained by buccal biopsy. The platform used is [HG-
U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array.  
BRB analysis shows that there are 7956 genes that are differentially expressed 
between smokers and non-smokers (p<0.05). Moreover, the signal intensities of all 
probes assigned to UGT1A probes were significantly changed at the FDR<0.05 
(Table 4.8; Figure 4.7). In addition, probesets annotated for UGT1A8-1A9 were 
upregulated, as well (Table 4.9; Figure 4.8). 
Furthermore, all probesets showed a less than two-fold upregulation when compared 
with non-smokers. In summary, oral mucosa cells were shown to be responsive to 
cigarette smoke in terms of UGT1A induction. 
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Table 4.8 The geometric mean of intensities corresponding to common UGT1A 
probesets in GSE17913 (p<0.05). 
Parametric p-
value 
FDR Non-smokers 
(Geom mean of 
intensities) 
Smokers 
(Geom mean of 
intensities) 
Fold-
change 
Probe set 
5.00E-07 0.000804 459.2 692.61 0.66 204532_x_at 
4.00E-07 0.000683 331.76 487.24 0.68 206094_x_at 
2.00E-07 0.000421 439.84 667.39 0.66 207126_x_at 
2.50E-06 0.00258 315.65 483.31 0.65 215125_s_at 
3.55E-05 0.0139 269.32 397.65 0.68 208596_s_at 
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Figure 4.7 UGT1A expression in oral mucosa of smokers and non-smokers 
according to GSE17913 (* p<0.05,**p<0.001). Results were given as geometric 
mean ± SD. 
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Table 4.9 The geometric mean of intensities corresponding to UGT1A8-1A9 
probeset in GSE17913 (p<0.05) 
Parametric p-
value 
FDR Non-smokers 
(Geom mean of 
intensities) 
Smokers 
(Geom mean 
of intensities) 
Fold-
change 
Probe set 
5.22E-05 0.016 62.88 97.56 0.64 221305_s_at 
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Figure 4.8  UGT1A6 (232654_s_at), UGT1A8 and 1A9 (221305_s_at) expression in 
oral mucosa of smokers and non-smokers according to GSE17913 (* p<0.05, 
**p<0.001). Results were given as geometric mean ± SD. 
 
GSE 16149: Oral mucosa 
GSE16149, on the other hand, is another dataset generated with buccal mucosa 
samples of individuals 87. In this array, [HG-U133_Plus_2] Affymetrix Human 
Genome U133 Plus 2.0 Array was used to detect the alterations that have occurred in 
global gene expression patterns of buccal mucosa of 4 smokers and 4 non-smokers. 
An interesting point is that there are two biological replicates from each individual 
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originating from either right or left cheek of the patient. Therefore, there are 8 RNA 
samples from each group. In addition, there are two samples not having a replicate, 
making a 9 sample for each group. It should be noted that we collectively used each 
replicate as a single sample, ignoring a distinction as right or left cheek. Future 
analyses might consider testing right or left cheek separately or using a repeated 
measures design for statistical analysis. 
With significance of p<0.05, there were 2755 genes that were differentially 
expressed; among which there was a UGT1A probeset (Table 4.10). However, since 
the expression level measured by this probeset is around the basal level, it was not 
considered significantly modified by smoking (Table 4.11; Figure 4.9; Figure 4.10). 
Although UGT1A8 and UGT1A9 probeset was expressed in oral mucosa it was not 
differentially expressed as in the previous dataset (Figure 4.8). Small size of this 
dataset might lead to such a discrepancy. 
Table 4.10 The geometric mean of intensities corresponding to common UGT1A 
probesets in GSE16149 (p<0.05)  
Parametric p-
value 
FDR Non-smokers 
(Geom mean of 
intensities) 
Smokers (Geom 
mean of 
intensities) 
Fold-
change 
Probe set 
0.0368421 0.883 13.6 10.44 1.3 206094_x_at 
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Figure 4.9 UGT1A expression in oral mucosa of smokers and non-smokers 
according to GSE16149 (* p<0.05,**p<0.001). Results were given as geometric 
mean ± SD. 
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Figure 4.10  UGT1A6 (232654_s_at), UGT1A8 and 1A9 (221305_s_at) expression 
in oral mucosa of smokers and non-smokers according to GSE16149 (* 
p<0.05,**p<0.001). Results were given as geometric mean ± SD. 
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GSE 8987: Nasal and Buccal Epithelial Cells 
This dataset is composed of two different array sets conducted with two different 
platforms and tissues 88. Since nose and mouth are two primary organs exposed to 
tobacco, the alterations in the gene expression of epithelial cells lining in these 
organs are of importance. Regarding this, the research team has isolated RNA from 
both nasal epithelial cells and buccal epithelial cells of current and never smokers. 
Total RNA isolated from mouth of 5 current and 5 non-smokers were run on [HG-
U133A] Affymetrix Human Genome U133A Array. Moreover, RNA from nose 
epithelium of 7 current and 8 non-smokers were run on [HG-U133A_2] Affymetrix 
Human Genome U133A 2.0 Array. Therefore, we have separated this dataset into 
two as GSE8987-Nasal Epithelium and GSE8987-Buccal Epithelium. 
Nasal Epithelial Cells 
BRB analysis has shown that there were UGT1A1 probesets that were significantly 
expressed besides 493 other genes (p<0.05) (Table 4.11). FDR analysis did not show 
significance, however, most likely due to small sample size of the study. The 
common UGT1A probesets showed a less than two-fold upregulation when 
compared with non-smokers (Figure 4.11). However, UGT1A8-1A9 probesets, 
although expressed, were not among those (Figure 4.12). 
Table 4.11 The geometric mean of intensities corresponding to common UGT1A 
probesets in GSE8987 (p<0.05). 
Parametric p-
value 
FDR Non-smokers 
(Geom mean 
of 
intensities) 
Smokers 
(Geom mean 
of 
intensities) 
Fold-
change 
Probe set 
0.0050582 1 383.65 507.27 0.76 204532_x_at 
0.0058929 1 292.89 391.25 0.75 206094_x_at 
0.0325089 1 397.4 496.5 0.8 207126_x_at 
0.0062479 1 184.77 257.47 0.72 215125_s_at 
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0.0013462 1 276.31 482.27 0.57 208596_s_at 
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Figure 4.11 UGT1A expression in nasal epithelium of smokers and non-smokers 
according to GSE8987 (* p<0.05,**p<0.001). Results were given as geometric mean 
± SD. 
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Figure 4.12 UGT1A8 and 1A9 (221305_s_at) expression in nasal epithelium of 
smokers and non-smokers according to GSE8987 (* p<0.05,**p<0.001). Results 
were given as geometric mean ± SD. 
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Buccal Epithelial Cells 
In the second part of the experiment, total RNA isolated from buccal epithelial cells 
was hybridized with [HG-U133A] Affymetrix Human Genome U133A Array. 
Interestingly none of the UGT1 probesets or UGT1A8-UGT1A9 probesets, which 
were expressed at very low levels, were significantly altered in buccal epithelial cells 
while there were genes affected in nasal epithelial cells (Figure 4.13 and Figure 
4.14).  
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Figure 4.13 UGT1A expression in buccal epithelium of smokers and non-smokers 
according to GSE8987 (* p<0.05,**p<0.001). Results were given as geometric mean 
± SD. 
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Figure 4.14 UGT1A8 and 1A9 (221305_s_at) expression in buccal epithelium of 
smokers and non-smokers according to GSE8987 (* p<0.05,**p<0.001). Results 
were given as geometric mean ± SD. 
 
GSE7895: Human airway bronchial epithelial cells 
GSE7895 is one of the arrays with detailed smoking history, indicating whether 
patients were former, current and never-smokers 89. This dataset tested the reversible 
and irreversible effects of tobacco on healthy individuals using bronchial epithelial 
cells isolated with fiberoptic bronchoscopy. Since long term effects of smoking can 
be reversible after quitting, this array contains samples of never, former and current 
smokers. The number of samples is as follows: 21 never smokers, 31 former smokers 
and 52 current smokers. Total RNA isolated from bronchial epithelium of individuals 
were hybridized with [HG-U133A] Affymetrix Human Genome U133A Array.                   
Smoker vs Non-smoker Comparison 
When the arrays were grouped as smokers (including current and former) and non-
smokers, with significance of p<0.05, there were 3141 genes that were differentially 
expressed among which there were common UGT1A probesets (Table 4.12) and the 
UGT1A8-1A9 probeset (Table 4.13). All of these probesets except one had an FDR 
level less than 0.1 indicating 10% false discovery rate. 
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When we compare the arrays as smokers and non-smokers, there was a significant 
increase in the intensities of common probesets (some close to two fold) and 
UGT1A8 and 1A9 specific probesets (Figure 4.15 and Figure 4.16). However, the 
expression level of UGT1A8-9 probeset was again at a very low level and the 
differential expression detected by class comparison is not reliable due to low 
expression.   
Table 4.12 The geometric mean of intensities corresponding to common UGT1A 
probesets in GSE7895 (p<0.05)  
Parametric p-
value 
FDR Non-smokers 
(Geom mean 
of intensities) 
Smokers 
(Geom mean 
of intensities) 
Fold-
change 
Probe set 
9.10E-06 0.00155 172.17 258.66 0.67 204532_x_at 
2.26E-05 0.00286 168.51 242.98 0.69 206094_x_at 
1.02E-05 0.00169 196.91 303.28 0.65 207126_x_at 
0.009617 0.158 112.31 145.39 0.77 208596_s_at 
1.22E-05 0.00181 78.05 135.78 0.57 215125_s_at 
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Figure 4.15 UGT1A expression in airway epithelium of smokers and non-smokers 
according to GSE7895 (* p<0.05,**p<0.001). Results were given as geometric mean 
± SD. 
Table 4.13 The geometric mean of intensities corresponding to UGT1A8-1A9 
probeset in GSE7895 (p<0.05) 
Parametric p-
value 
FDR Non-smokers 
(Geom mean of 
intensities) 
Smokers (Geom 
mean of 
intensities) 
Fold-
change 
Probe set 
0.0025816 0.0742 18 20.41 0.88 221305_s_at 
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Figure 4.16 UGT1A8 and 1A9 (221305_s_at) expression in airway epithelium of 
smokers and non-smokers according to GSE8987 (* p<0.05,**p<0.001). Results 
were given as geometric mean ± SD. 
 
Never vs Current vs Former Comparison 
When arrays were grouped based on their smoking status, there were 4841 genes that 
were differentially expressed among current, former and never smokers; among  
these probesets there were the common UGT1A probesets (p<0.05; FDR<0.05) 
(Table 4.14; Figure 4.17). Although, UGT1A8-1A9 probeset was reported as 
differentially expressed; the fold change is very low while the expression of this 
probeset was not different from the background levels on the array (Table 4.15; 
Figure 4.18). 
A comparison between former, current and never smokers show that the levels of 
UGT1A genes as a whole were highest at current smokers. The fold difference 
between former and never smokers were not as much as the alteration between 
current smokers and the rest. This implies that the effects of cigarette smoke with 
regard to UGT1A expression are reversible in case when the individual quit smoking.  
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Table 4.14 The geometric mean of intensities corresponding to common UGT1A 
probesets in GSE7895 (p<0.05)  
Parametric p-
value 
FDR Current 
Smoker 
(Geom mean 
of intensities) 
Former 
Smoker (Geom 
mean of 
intensities) 
Never 
Smoker 
(Geom mean 
of intensities) 
Probe set 
< 1e-07 < 1e-07 306.71 194.37 172.17 204532_x_at 
< 1e-07 < 1e-07 282.5 188.7 168.51 206094_x_at 
< 1e-07 < 1e-07 362.86 224.48 196.91 207126_x_at 
< 1e-07 < 1e-07 172.86 108.75 112.31 208596_s_at 
< 1e-07 < 1e-07 170.85 92.36 78.05 215125_s_at 
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Figure 4.17 UGT1A expression in airway epithelium of current, former and non-
smokers according to GSE7895 (* p<0.05,**p<0.001). Results were given as 
geometric mean ± SD. 
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Table 4.15 The geometric mean of intensities corresponding to UGT1A8-1A9 
probeset in GSE7895 (p<0.05) 
Parametric p-
value 
FDR Current 
Smoker 
(Geom mean 
of intensities) 
Former 
Smoker 
(Geom mean 
of intensities) 
Never 
Smoker 
(Geom mean 
of intensities) 
Probe set 
0.0102216 0.107 20.31 20.59 18 221305_s_at 
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Figure 4.18 UGT1A8 and 1A9 (221305_s_at) expression in airway epithelium of 
current, former and never smokers according to GSE8987 (* p<0.05,**p<0.001). 
Results were given as geometric mean ± SD. 
 
GSE 994: Human airway epithelial cells 
GSE994 dataset included arrays that were run with samples from intra-pulmonary 
airway epithelial cells of 34 current smokers, 23 never smokers and 18 former 
smokers 90. The samples were obtained by brushing. The arrays run with [HG-
U133A] Affymetrix Human Genome U133A Array were analyzed with BRB-Array 
tools in two parts.  
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Smoker vs Non-smoker Comparison 
When smokers and non-smokers were compared, with significance of p<0.05, there 
were 3827 genes that were differentially expressed. Among these all common 
UGT1A probesets except one (208596_s_at) were significant at FDR<0.05 (Table 
4.16). 
GSE994 showed that the highest expression of UGT1A genes was present at airways 
of smokers in comparison with non-smokers (Figure 4.19). Again UGT1A8-A9 
probeset was not expressed to detectable levels by the microarray probeset (Figure 
4.20). 
Table 4.16 The geometric mean of intensities corresponding to common UGT1A 
probesets in GSE994 (p<0.05). 
Parametric p-
value 
FDR Non-smokers 
(Geom mean 
of intensities) 
Smokers 
(Geom mean 
of intensities) 
Fold-
change 
Probe set 
3.00E-06 0.000743 99.28 148.98 0.67 204532_x_at 
0.0003131 0.0176 104.19 139.25 0.75 206094_x_at 
3.56E-05 0.00422 111.33 166.21 0.67 207126_x_at 
0.0108195 0.142 74.38 94.51 0.79 208596_s_at 
5.30E-06 0.00111 46.98 83.41 0.56 215125_s_at 
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Figure 4.19 UGT1A expression in airway epithelium of smokers and non-smokers 
according to GSE994 (* p<0.05,**p<0.001). Results were given as geometric mean 
± SD. 
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Figure 4.20 UGT1A8 and 1A9 (221305_s_at) expression in airway epithelium of 
smokers and non-smokers according to GSE994 (* p<0.05,**p<0.001). Results were 
given as geometric mean ± SD. 
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Former vs Current vs Never Comparison 
When the arrays were grouped according to their status of smoking, there were 3369 
genes that were differentially expressed with significance at p<0.05 among former, 
current and never smokers. In this list there were UGT1A genes with FDR levels less 
than 0.05 (Table 4.17). The results indicated that current smokers had relatively and 
significantly higher expression when compared with either the former or never 
smokers suggesting that the effects of smoking on UGT1A expression were 
reversible (Figure 4.21). Furthermore, the upregulation of genes do not include 
UGT1A8-1A9 genes as implicated in the graph since this probeset was not 
detectably measured (Figure 4.22). 
Table 4.17 The geometric mean of intensities corresponding to common UGT1A 
probesets in GSE994 (p<0.05) 
Parametric p-
value 
FDR Current 
Smoker (Geom 
mean of 
intensities) 
Former 
Smoker (Geom 
mean of 
intensities) 
Never 
Smoker 
(Geom mean 
of intensities) 
Probe set 
< 1e-07 < 1e-07 169.16 117.21 99.28 204532_x_at 
1.00E-06 0.000237 156.06 112.28 104.19 206094_x_at 
< 1e-07 < 1e-07 194.42 123.61 111.33 207126_x_at 
0.0002031 0.0142 106.21 75.8 74.38 208596_s_at 
< 1e-07 < 1e-07 102.5 56.51 46.98 215125_s_at 
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Figure 4.21 UGT1A expression in airway epithelium of current, former and never 
smokers according to GSE994 (* p<0.05,**p<0.001). Results were given as 
geometric mean ± SD. 
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Figure 4.22 UGT1A8 and 1A9 (221305_s_at) expression in airway epithelium of 
current, former and never smokers according to GSE994 (* p<0.05,**p<0.001). 
Results were given as geometric mean ± SD. 
 
GSE10072: Lung adenocarcinoma cells 
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This study was different among the others in that it focused on the lung 
adenocarcinoma cells 91. There were 58 tumor tissue derived cells and 49 non-tumor 
tissue derived cells that were analyzed. These cells were isolated from 28 current and 
26 former smokers in addition to 20 never smokers. RNA from the samples was run 
on [HG-U133A] Affymetrix Human Genome U133A Array. A comparison between 
non-smokers and smokers showed that no UGT1A genes were significantly changed 
(p<0.05). Furthermore, a comparison between former and current smokers showed 
that no UGT1A genes were significantly changed, as well (p<0.05). However, the 
dataset includes tumors and non-tumor adjacent samples from the same patient thus a 
paired significance analysis might also be performed in the future. 
GSE19027 Human airway bronchial epithelial cells 
This study defined the genes that may identify the transition to lung cancer. 
Therefore, they analyzed smokers and non-smokers with and without lung cancer in 
addition to healthy individuals 92. Since the arrays belonging to healthy individuals 
are derived from GSE994, and to prevent re-use of the same samples, we have 
excluded these arrays from analysis and normalized the rest. Moreover, one array 
was excluded due to an error while importing the data 
(GSM470852_s54p103B1.CEL).  
The chip type in this dataset is [HG-U133A] Affymetrix Human Genome U133A 
Array. There were 3 never smokers, 17 current smokers without cancer, 8 former 
smokers without cancer, 9 current smokers with cancer and 12 former smokers with 
cancer analyzed. The samples isolated were bronchial epithelial cells obtained via 
bronchoscopy.  
The class comparison among smokers and non-smokers were done by grouping the 
samples into two as healthy and persons with cancer.  
Comparison among healthy individuals 
With significance level of p<0.05 there were 5687 genes differentially expressed 
among which there were UGT1A genes (Table 4.18). In all common UGT1A 
probesets, a significant increase in current smokers was observed while the 
expression in former and never smoker were similar to each other (FDR<0.16; 
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Figure 4.23). When the probeset specific for UGT1A8-1A9 genes was surveyed, no 
significant fold-difference was observed (Figure 4.24). 
Table 4.18 The geometric mean of intensities corresponding to common UGT1A 
probesets in GSE19027 (p<0.05) 
Parametric p-
value 
FDR Current 
Smoker 
(Geom mean 
of intensities) 
Former 
Smoker 
(Geom mean 
of intensities) 
Never Smoker 
(Geom mean of 
intensities) 
Probe set 
0.0022436 0.101 364.66 236.63 209.92 204532_x_at 
0.0119296 0.125 366.16 248.11 243.97 206094_x_at 
0.0023689 0.101 402.23 241.46 245.55 207126_x_at 
0.0309416 0.164 195.13 129.19 115.13 208596_s_at 
0.0044015 0.104 180.44 93.93 88.23 215125_s_at 
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Figure 4.23 UGT1A expression in airway epithelium of healthy current, former and 
non-smoker according to GSE19027 (* p<0.05,**p<0.001). Results were given as 
geometric mean ± SD. 
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Figure 4.24  UGT1A8 and 1A9 (221305_s_at) expression in airway epithelium of 
healthy current, former and never smokers according to GSE19027 (* p<0.05, 
**p<0.001). Results were given as geometric mean ± SD. 
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Non-smoker vs Smoker Comparison among healthy individuals 
With a significance level of p<0.05 there were 763 genes that were differentially 
expressed among which there were no UGT1A genes. It was an unexpected result; 
however, it may have stemmed from the relatively small number of samples in non-
smokers’ group.  
Comparison among cancer patients 
With a significance level of p<0.05 there were 910 genes differentially expressed 
among which there were UGT1A genes (Table 4.19) although the FDR level was 
high possibly due to low sample size. A fold change of 1.5 was observed among 
current and former smokers with lung cancer (Figure 4.25). The high and significant 
difference between current and former smokers was not due to expression changes in 
UGT1A8-1A9 (Figure 4.26). 
Table 4.19 The geometric mean of intensities corresponding to common probesets in 
GSE19027 (p<0.05) 
Parametric p-
value 
FDR Current Smoker 
Geom mean of 
intensities) 
Former Smoker 
(Geom mean of 
intensities) 
Fold-
change 
Probe set 
0.0054486 0.917 378.69 221.66 1.71 204532_x_at 
0.0150579 1 360.49 242.7 1.49 206094_x_at 
0.0157856 1 407.62 236.4 1.72 207126_x_at 
0.0427523 1 159.86 91.67 1.74 215125_s_at 
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Figure 4.25 UGT1A expression in airway epithelium of current and former smokers 
with lung cancer according to GSE19027 (* p<0.05,**p<0.001). Results were given 
as geometric mean ± SD. 
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Figure 4.26  UGT1A8 and 1A9 (221305_s_at) expression in airway epithelium of 
current and former smokers with lung cancer according to GSE19027 (* p<0.05, 
**p<0.001). Results were given as geometric mean ± SD. 
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GSE3212: Human alveolar macrophages 
In this dataset, the aim was to comprehend the gene expression changes in alveolar 
macrophages in healthy smokers and non-smokers. Cells were obtained by 
bronchoalveolar lavage 93. This dataset included RNA from 5 healthy smokers and 5 
non-smokers; which were hybridized on [Hu6800] Affymetrix Human Full Length 
HuGeneFL Array. When the data were analyzed there were 283 genes differentially 
expressed with a significance value of p<0.05; among which there was no UGT1A 
probeset.  There was considerable expression of common UGT1A probesets though. 
There are studies proving the presence of UGT1A activity and their inducibility by 
polycyclic aromatic hydrocarbon in alveolar macrophages 94. However, our results 
proposed that their levels are not changed by smoking.   
GSE8823: Human alveolar macrophages 
GSE 8823 focused on alveolar macrophages of healthy smokers and non-smokers 
isolated by bronchoalveolar lavage 95. The platform used was [HG-U133_Plus_2] 
Affymetrix Human Genome U133 Plus 2.0 Array. Dataset combined samples of 11 
non-smokers and 13 smokers. BRB-analysis showed that among 6033 genes, no 
UGT1A genes were significantly changed (p<0.05) even though they are expressed.  
GSE13896: Human alveolar macrophages 
This dataset was generated to ask the question whether alveolar macrophage 
polarization was related with smoking and COPD 96. The arrays carrying samples 
from patients with COPD were excluded from the analysis. In addition, in this 
dataset, there were arrays showing redundancy with GSE8823.  Those were excluded 
as well. The platform used was [HG-U133_Plus_2] Affymetrix Human Genome 
U133 Plus 2.0 Array. The class comparison among smokers and non-smokers 
showed that there was no UGT1A gene that was differentially expressed (p<0.05). It 
is important to note that common probesets detected a considerable level of 
expression. 
GSE12585: Human peripheral lymphocytes 
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This subset series was part of a larger study, collected under the name of GSE12587.  
The superseries GSE12587 combined both in vivo and in vitro data.  In vivo data 
were composed of human peripheral lymphocytes isolated from smokers. In vitro 
data, on the other hand, was generated by culturing the isolated human peripheral 
lymphocyte cells with or without smoke-condensate. We will be focusing on 
GSE12525, the subseries with in vivo data. The basic comparison underlying this 
study was between heavy and light smokers. The platform used was [HG-U133A] 
Affymetrix Human Genome U133A Array and there were 10 heavy and 13 light 
smokers attending this study. Among 922 genes, no UGT1A genes were identified as 
significantly changed (p<0.05). 
When we analyzed this array, we could not see a significant change in UGT1A 
expression although there is considerable expression. The reason may be that 
UGT1A expression may not be that responsive to the level of smoking. 
4.2 Statistical analysis of UGT1A probesets from SW620 Nicotine Treatment 
Experiment 
Previous studies performed by Onur Kaya 78 showed that nicotine increased the cell 
survival as evidenced by an MTT assay even at a lower dose of 10nm but was 
effective also in 1 and 10µM. A microarray experiment was also performed 78 and 
the results of these arrays were now re-analyzed in the context of UGT1A probesets 
using BRB tools. When the probesets assigned to UGT1A locus were surveyed 
individually, it was seen that they were upregulated significantly in serum starved 
and nicotine treated cells (p<0.05; and FDR<0.05 except for 221305_s_at) (Table 
4.20). Furthermore, this upregulation could not be observed in cells that were 
nicotine treated and grown at 10% FBS containing medium (Table 4.21). At this 
point, verification of the data and more detailed analysis of the results were needed to 
speculate that nicotine induced proliferation and UGT1A expression under serum 
starvation. 
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Table 4.20 The geometric mean of intensities corresponding to common UGT1A 
probesets in serum starved and nicotine treated SW620 cells according to the 
microarray performed in our lab 
Parametric 
p-value 
FDR 0.1% FBS  
Control 
0.1%FBS  
1uM Nicotine   
Fold-
change 
Probe set 
0.0002279 0.0102 348.45 639.51 0.54 204532_x_at 
0.0006852 0.0195 252.23 444.32 0.57 206094_x_at 
0.0002348 0.0103 328.15 577.7 0.57 207126_x_at 
1.30E-06 0.000397 189.43 565.42 0.34 208596_s_at 
5.10E-06 0.00102 107.11 385.29 0.28 215125_s_at 
0.0357341 0.201 25.87 19.68 1.31 221305_s_at 
 
When nicotine treated cells from serum starved and serum replenished group were 
analyzed using the BRB Array Tools class comparison tool, it became evident that 
UGT1A expression induction was unique to nicotine treated starved SW620 cells 
(Table 4.21). 
Table 4.21 The geometric mean of intensities corresponding to common UGT1A 
probesets in 48h Nicotine-treated SW620 cells according to the microarray 
performed in our lab 
Parametri
c p-value 
FDR 0.1% FBS 
Control 
0.1%FBS 
1uM 
Nicotine 
10% FBS 
Control 
10% FBS 
1uM 
Nicotine 
Probe set 
4.77E-05 0.00113 348.45 639.51 255.26 267.17 204532_x_at 
6.38E-05 0.00135 252.23 444.32 193.44 182.78 206094_x_at 
2.30E-06 0.000163 328.15 577.7 222.69 213.72 207126_x_at 
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2.00E-07 3.38E-05 189.43 565.42 150.35 145.34 208596_s_at 
2.20E-06 0.00016 107.11 385.29 65.8 63.15 215125_s_at 
 
For further demonstration of how common UGT1A probesets were changed 
drastically when serum starved cells are treated with 1µM nicotine, we have plotted a 
dot graph (Figure 4.27). Furthermore, a heatmap was plotted using Cluster 3.0 and 
Treeview (Figure 4.28). 
 
Figure 4.27  Mean intensities of each UGT1A probeset in 48h Nicotine-treated and 
untreated SW620 cells (starved or serum-replenished).  
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Figure 4.28Treeview image of UGT1A probesets in 48h nicotine-control treatment 
in SW620 experiment (p<0.001). Green and red colors indicate a reduction and 
induction of expression, respectively, when each gene is normalized to its median.  
4.3 Microarray Validation by qRT-PCR 
4.3.1  Melt Curve Analysis 
At the end of each qRT-PCR run, it is essential to check the melt curves and agarose 
gels for the validity and reliability of each reaction. We have analyzed each PCR run 
as below before inclusion in analyses: 
- Dissociation curve of each sample should be checked. Each sample should present 
a curve specific to a particular amplicon centered on the same axis between 80°C- 
95°C, and indicating a Tm of a double strand DNA with sizes of at least 80bp. 
Samples with an additional peak of primer-dimers are included only if the dimer 
curve is negligible relative to the target curve. 
- Each sample should be run on Agarose gel and checked with respect tothe presence 
of the expected target amplicon and the relatively higher intensity of the target band 
to other bands, if any. 
 
Depending on these parameters, each PCR reaction was individually evaluated and 
included in the analyses, accordingly (see for examples: Figures 4.29-4.31). 
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As Figure 4.29 shows, all the results in this reaction have a concrete dissociation 
peak on one axis.  
 
Figure 4.29 A demonstration  melt curve belonging to samples that all pass the 
inclusion criteria. Blue curves indicate the samples while red curve belongs to 
negative control. 
Figure 4.30 shows a gel photo including a sample with higher intensity band for 
primer-dimer. This sample was excluded, as expected. 
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Figure 4.30 Arrows indicate the samples to be excluded for analysis in a 
demonstration gel photo. 
Figure 4.31 demonstrates a reaction with some samples that are excluded. The 
sample with longer size, as indicated with a band higher than the other was excluded, 
as expected. Furthermore, the sample with additional band was excluded, too, since it 
was not possible to assign which band was responsible for Ct value detected.  
 
Figure 4.31 Arrows indicate the samples to be excluded for analysis in a 
demonstration gel photo. 
 
4.3.2  Primer Efficiencies  
The expression of UGT1A isoforms was studied using qRT-PCR analysis based on 
primers reported by Nakamura et al. (2008)20. Before use, the primer efficiency of 
each gene was calculated. Since efficiency calculations require at least five Ct values 
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in a row, the reactions were run with cDNA in which there are abundant expression 
of the genes. cDNA profile was determined according to Nakamura et al. (2008)20. E 
values for each primer couple were given in Table 4.22. 
Most likely because amplicon size is large or simply due to its low expression the 
efficiency calculated for UGT1A7 could not be reliably assessed. That’s why; its E 
value was set as 2. New primer pairs should be tried to assess the expression of 
UGT1A7 gene. 
Table 4.22 Efficiency values calculated for each primer couple with the same kit 
used. 
Gene name Efficiency (E) cDNA used for efficiency 
reactions 
UGT1A1 1.86 MCF-7 
UGT1A3 1.99 A pool of HepG2, Huh-
7,Caco-2, PLC, NCIH69, 
SNU-475 cDNA 
UGT1A4 2.28 SW620  
UGT1A5 2.19 SW620  
UGT1A6 1.86 MCF-7 
UGT1A7 2* - 
UGT1A8 1.99 A pool of HepG2, Huh-
7,Caco-2, PLC, NCIH69, 
SNU-475 cDNA 
UGT1A9 2.03 A pool of HepG2, Huh-
7,Caco-2, PLC, NCIH69, 
SNU-475 cDNA 
UGT1A10 1.95 A pool of HepG2, Huh-
7,Caco-2, PLC, NCIH69, 
SNU-475 cDNA 
ANLN 2.1 SW620 
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MKI67 2.27 SW620 
 
4.3.3  Selection of a Reference Gene for Nicotine Treatment of Starved Cells 
As indicated in the paper of Pfaffl et al. (2004) 45, for a successful analysis with 
relative expression calculations in qRT-PCR, the stability of internal standards are 
important. Taking this criterion into account, we have determined the expression 
levels of five potential internal standard candidates, which have been used as 
reference genes in other studies. GAPDH is the most utilized reference gene in 
molecular biology. PPIA gene was shown to be a reliable standard gene for breast 
cancer tissues 97.  Furthermore, some ribosomal proteins (RPL) have been shown as 
the best housekeeping gene in mice exposed to oxidative stress 98. 
As can be seen in Figure 4.32, the expression levels of GAPDH were very close in 
both the control and nicotine treated samples, indicating its strength as a reference 
gene. In addition, Ct values of PPIA in both samples were not divergent, either. On 
the other hand, ribosomal proteins were consistently downregulated under nicotine 
treatment, which raises an interesting point that warrants further study. Accordingly, 
GAPDH and PPIA were found to be stable and thus were considered as two probable 
endogenous references for serum starved and nicotine treated SW620 cells. Based on 
this observation, we have normalized the expression of target genes to GAPDH in 
each sample. Future analyses might consider using a combination of reference genes. 
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Figure 4.32 Expression values of GAPDH, PPIA, RPL3,  RPL10,  RPLP0 in serum 
starved SW620 cells. Results were given as Ct values and asteriks indicated 
significance at p<0.05 level. 
4.3.4  qRT-PCR results as analyzed by the modified delta-delta-ct method 
With the purpose of further verifying the results obtained from microarray analysis 
as shown above, we performed a series of quantitative real-time PCR (qRT-PCR) 
experiments.  
As a starting point, two genes representatives of growth induction were chosen to be 
analyzed. In case when ANLN and MKI67 mRNA levels were upregulated 
significantly by nicotine, this would mean that cells were triggered for proliferation. 
When cDNA of cells that were incubated with different concentrations of nicotine in 
the presence of 10% FBS, these two genes did not show any alterations in expression 
suggesting that only starved cells responded to nicotine by increasing cell 
proliferation response  (Figure 4.33  and Figure 4.34). This was confirmatory of the 
MTT experiments done previously78. 
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Figure 4.33 Analysis of cell proliferation in Nicotine-treated SW620 cells in 
10%FBS media via Quantitative RT-PCR of MKI67 levels. 
 
Figure 4.34 Analysis of cell proliferation in Nicotine-treated SW620 cells in 
10%FBS media via Quantitative RT-PCR of ANLN levels. 
All together, these showed that cells grown under normal conditions were not 
responsive to increasing concentrations of nicotine within 48h. 
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On the other hand, three sets of cDNA from cells that were either serum starved or 
serum starved and 1µM Nicotine treated were analyzed in terms of ANLN and 
MKI67 levels. A significant increase in the expression of both genes were observed 
when cells were exposed to 1µM Nicotine (p<0.05) (Figure 4.35).  
 
Figure 4.35 Analysis of cell proliferation in Nicotine-treated SW620 cells in 
0.1%FBS media via quantitative RT-PCR of ANLN and MKI67 levels. Results were 
given as mean ± SD (DF=5, F-value= 541.41, p<0.001 for ANLN, DF=5, F 
value=79.91, p<0.001 for MKI67). 
To sum up, we have seen that SW620 cells kept in the presence of 10% FBS did not 
respond to changing nicotine levels in terms of proliferation 78 and this also was now 
verified at the transcriptomic level using qRT-PCR on a dose-curve of nicotine. 
Moreover, when cells were serum starved 1µM nicotine upregulated the genes 
related with growth induction. ANLN and MKI67 have been shown to be related 
with proliferation in literature 99-100. This picture was consistent with what our 
microarray analyses have shown. From this point, we expected to see the significant 
change in glucuronidation genes as the BRB analyses have pointed out based on the 
probeset expression values. In addition, it was important to ask whether the 
deregulation of UGT1A locus occurs in an isoform-specific manner. Isoform 
specificity could not be assessed using microarrays in our case thus a more specific 
qRT-PCR study has been essential part of our study. 
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The same cDNA set used in ANLN and MKI67 expression experiments were utilized 
for UGT1A expression determination. The expression levels of each gene were 
normalized according to the endogenous levels of GAPDH mRNA and relative fold 
changes in each gene are represented with two bar graphs as shown below: 
qRT-PCR with UGT1A isoforms in serum deprived cells showed there was a change 
in expression levels of all UGT1A isoforms to relative degrees (Figure 4.36 and 
Figure 4.37). However, while some of the changes were statistically significant, 
some were not. In addition, most of the results belonging to UGT1A8 primer fail to 
pass the exclusion criterions. It may be because there are PCR inhibitors for 
UGT1A8 in SW620 cDNA since the E value of UGT1A8 could be determined in a 
pool of cDNA from different cell lines. Therefore, their results could not be 
presented. For the assessment of statistical significance, we also considered multiple 
test correction criterions and calculated a Benferroni p-value, which was 0.00625. p 
values under 0.00625 were defined as significant. 
According to Figure 4.36, UGT1A1, UGT1A3, UGT1A4 and UGT1A6 genes were 
the isoforms that were very significantly upregulated with 1µM Nicotine exposure in 
serum starved SW620 cells (p<0.0065). Relative fold changes of UGT1A1 and 
UGT1A3 were 10 and 13, respectively, and were statistically significant with p-
values of p<0.001 (DF=5, F-value= 514.24 for UGT1A1, DF=5, F value=88.39 for 
UGT1A3). UGT1A6 upregulation was a significant increase with a fold change of 22 
(DF= 5, F-value= 85.29 p-value=0.001) (Figure 4.36).  Furthermore, UGT1A5 was 
another isoform that is being upregulated, but not significantly according to 
Benferroni correction (DF=5, F-value=19.92 p-value=0.011) (Figure  4.36). The 
upregulation of UGT1A4 was highest among the others with almost 90-folds; 
suggesting that it has a major role in drug metabolism carried out in SW620 cells 
(DF=5, F-value=49.83 p-value=0.002). In addition, UGT1A7 levels seemed to 
increase with nicotine but not significantly and with high variability (Figure 4.37) 
(DF= 3, F-value= 1.25 p-value=0.379). This gene requires new primer couples. 
As a last note, UGT1A9 and UGT1A10 expression levels were very low as measured 
by the qRT-PCR experiments also complementing the findings from microarray 
probeset results. The changes in these genes were not significant (Figure 4.37) 
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(DF=3, F-value=0.02 p-value=0.903 for UGT1A9) (DF=5, F-value=1.09 p-
value=0.356 for UGT1A10). 
Isoform Specific Expression of UGT1A genes
 in Serum starved SW620 cells
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Figure 4.36 The expression levels of UGT1A isoforms normalized to GAPDH 
mRNA levels. Results were given as mean ± SD. (*indicates the significance 
corrected with Benferroni) 
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Isoform Specific Expression of UGT1A genes
 in Serum starved SW620 cells
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Figure 4.37 The expression levels of UGT1A isoforms normalized to GAPDH 
mRNA levels. Results were given as mean ± SD.  
In order to verify that upregulation of UGTs as a response to nicotine treatment was 
only observed in cells that were serum starved, we have checked the expression 
levels of UGT1A6 in normally grown cells. The reason for choosing UGT1A6 is that 
it was one of the isoforms most affected under nicotine treatment. The result of this 
experiment demonstrated that UGT1A6 was overexpressed in normally grown 
SW620 cells with 48h nicotine treatment (Figure 4.38 ).  
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Figure 4.38 The expression level of UGT1A6 normalized to GAPDH mRNA levels 
in SW620 cells grown with 10%FBS-containing medium.  
These results further confirm the microarray results, indicating that modulation of 
UGTs with 48h nicotine treatment is specific to serum-deprived SW620 cells.  
4.4  in silico Promoter Analysis of UGT1A isoforms 
Observing that with nicotine addition, only certain UGT1A isoforms were being 
upregulated while no change could be observed in particular isoforms has raised an 
important question. In addition, the magnitude of upregulation was different among 
the overexpressed isoforms. When these particular isozymes were surveyed in terms 
of their substrate specificity, nothing common for these isozymes could be found. 
Moreover, their relation with nicotine glucuronidation was absent, as well. At this 
point, an important question was asked regarding the association between UGT1A 
expression and sequence. 
The starting point was analysis of Exon 1 and promoter region of 300bp. Each 
isoform was aligned via ClustalW software to see whether there was a clustering of 
the isozymes 101. Accordingly, there was a grouping of genes into two based on the 
sequence similarity in the corresponding regions (Figure 4.39). The important thing 
 was that 
nicotine fr
 
Figure 4.3
each UGT
Furthermo
regions, th
between s
 
Figure 4.4
isofom. P
administra
The prom
transcripti
isoforms a
we analyz
As shown
promoters
these two 
om the othe
9 Alignme
1A isofom 
re, when t
is clusteri
equence an
0 Alignme
ink box 
tion while 
oter regio
on factor. T
nd absent i
ed the prom
 in Figure
 of each UG
groups co
rs.  
nt based o
he alignme
ng of gene
d expressio
nt based o
indicates 
grey box di
ns carry c
herefore, t
n the others
oter region
 4.41, ther
T1A isofo
70
uld well d
n promoter
nt was carr
s was ma
n of UGTs 
n promoter 
the genes
splayed the
ertain mo
he presence
 could answ
s of all UG
e are com
rm.  
 
iscriminate
 region (30
ied out wi
intained; fu
(Figure 4.4
region (30
 that are
 ones witho
tifs, enabl
 of motifs,
er many q
T1A isofo
mon and s
 the genes
0nt upstrea
th sequenc
rther supp
0). 
0nt upstream
 upregulat
ut change i
ing the bi
 found in d
uestions. B
rms with M
pecific mo
 deregulat
m) and Ex
es within p
orting the 
) of each 
ed with 
n gene exp
nding of 
eregulated 
ased on this
EME softw
tifs, locate
ed with 
on 1 of 
romoter 
relation 
 
UGT1A 
nicotine 
ression.  
relevant 
UGT1A 
 notion, 
are 102. 
d in the 
 
71 
 
 
Figure 4.41 MEME result of promoter regions belonging to all UGT1A isoforms 
These results suggest that expression and sequence of UGT1A isoforms might be 
associated and warrants further analysis.
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5. CONCLUSION AND DISCUSSION 
Here in this report, we showed that UGT1A isoforms were responsive to smoking 
and to nicotine, using in vivo public microarray data and our in vitro SW620 colon 
cancer nicotine exposure model, respectively. In vivo datasets from GEO repository 
were carefully selected and analyzed to assess whether smokers have higher UGT1A 
expression and also whether there is a difference between current and former 
smokers. For the first time we showed that, in multiple epithelial tissues, smokers 
significantly overexpress UGT1A gene clusters.  For all microarray evaluation steps, 
a uniform bioinformatics tool and a set of protocols were used. Being integrated 
software which enables statistical analysis and visualization, BRB array tools has 
been chosen for data analysis of microarray results. Another reason for preference of 
this analytical software was that it had an extensive network allowing access to 
several genomic websites and analysis tools. BRB Tools also provides a raw p-value 
and its associated FDR value, allowing for multiple test correction. The use of 
Affymetrix microarrays with common probesets helped us to incorporate three 
different platforms. 
We focused on arrays performed on healthy individuals but not the COPD patients 
since we cannot be sure that changes in UGT1A expression merely stem from 
smoking phenotype. However, a few cancer datasets also were analyzed. The overall 
scheme of arrays analyzed included a combination of number of arrays conducted in 
airway epithelium, oral and nasal mucosa, in members of immune system and 2 
arrays with samples from lung adenocarcinoma.  
The overall scheme from re-analysis of the above mentioned studies were 
summarized in Table 5.1, Table 5.2, Table 5.3 and Table 5.4.
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Table 5.1 Datasets run on various tissues isolated from healthy individuals 
Array 
Name 
Platform Origin of tissue/cells Smokers  
(n) 
Non-
smokers 
(n) 
Citation Result 
GSE4635 Affymetrix Human Genome 
U133A Array 
Large airway epithelium 5 (all 
current) 
5 PMID: 19357784 UGT1A expression of smokers 
was significantly upregulated 
(p<0.05) by an average of 2 fold 
change constant as compared to 
non-smokers. Expression of 
UGT1A8-1A9 was very low. 
GSE4498 Affymetrix Human Genome 
U133 Plus 2.0 Array 
Small airway epithelium 12 10 PMID: 17115125 
PMID: 19106307 
 
Smokers have at least twice the 
expression of UGT1A isoforms 
when compared with non-
smokers (FDR<0.05). UGT1A6 
probeset detected a very low 
expression in non-smokers, 
which again was doubled in 
smokers. UGT1A8 and 
UGT1A9 probesets detected 
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very low expression. 
GSE10006 Affymetrix Human Genome 
U133 Plus 2.0 Array 
Large airway epithelium 38 20 PMID: 18832735 Approximately three fold 
upregulation of UGT1A 
common probesets were 
observed in smokers. UGT1A6 
was upregulated by less than 
two fold constant. However, 
1A8 and 1A9 expressions were 
low and changes were not 
significant (FDR>0.05). 
GSE17913 Affymetrix Human Genome 
U133 Plus 2.0 Array 
Oral mucosa 39 40 PMID: 20179299 Common UGT1A probesets 
were significantly changed with 
less than two-fold upregulation 
at the FDR<0.05 in smokers. In 
addition, probesets annotated for 
UGT1A8-1A9 were upregulated 
(FDR<0.05). 
GSE16149 Affymetrix Human Genome 
U133 Plus 2.0 Array 
Buccal Mucosa 9 9 PMID: 20576139 One common probeset detected 
a very low expression, whose 
changes are not significant 
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(p>0.05). UGT1A8-1A9 
probeset levels were high but 
did not show difference among 
smokers and non-smokers. 
GSE8987-
Nose 
Affymetrix Human Genome 
U133A 2.0 Array 
Nose 7 8 PMID: 18513428 The common UGT1A probesets 
showed a less than two-fold 
upregulation when compared 
with non-smokers. UGT1A8-
1A9 probesets were expressed, 
but not alter significantly. 
GSE8987-
Mouth 
Affymetrix Human Genome 
U133A Array. 
Mouth 5 5 PMID: 18513428 Although expressed, the 
expression levels of common 
probesets did not show a 
significant change as well as 
UGT1A8-1A9 probesets. 
GSE3212 Affymetrix Human Full 
Length HuGeneFL Array 
Alveolar Macrophages 5 5 PMID: 16520944 The probeset for UGT1A 
detected epxression at moderate 
levels;yet, there was not a 
change among smokers and non-
smokers. 
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GSE8823 Affymetrix Human Genome 
U133 Plus 2.0 Array 
 
Alveolar Macrophages 13 11 PMID: 18587056 Although expressed, the 
expression levels of common 
probesets did not show a 
significant change. UGT1A8-
1A9 probesets detected very low 
expression. 
GSE13896 Affymetrix Human Genome 
U133 Plus 2.0 Array 
Alveolar Macrophages 22 13 PMID: 19635926 Although expressed, the 
expression levels of common 
probesets did not show a 
significant change. UGT1A8-
1A9 probesets detected very low 
expression. 
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Table 5.2 Datasets utilizing samples from current, former and never smokers 
Array 
Name 
Platform Origin of tissue/cells Current 
Smokers  
(n) 
Former 
Smokers 
(n) 
Never 
smokers 
(n) 
Citation Result 
GSE7895 Affymetrix Human Genome 
U133A Array 
Bronchial epithelium 52 31 21 PMID: 17894889 There was a significant 
change in levels of 
common probesets and 
the highest value 
belonged to current 
smokers (p<0.05; 
FDR<0.05). UGT1A8-
1A9 expression was 
very low and not 
significantly changed. 
GSE994 Affymetrix Human Genome 
U133A Array 
Intra-pulmonary 
airway epithelium 
34 18 23 PMID: 15210990 All common UGT1A 
probesets except one 
(208596_s_at) were 
significantly changed at 
FDR<0.05 and highest 
in current smokers. 
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Table 5.3 Datasets utilizing samples from cancer and healthy patients 
Array 
Name 
Platform Origin of tissue/cells Current 
Smokers  
(n) 
Former 
Smokers 
(n) 
Never 
smokers (n) 
Citation Result 
GSE10072 Affymetrix Human Genome 
U133A Array 
Lung 
adenocarcinoma cells 
and non-tumor tissues 
16 healthy, 
24 tumor 
17 healthy, 
18  tumor 
13 healthy, 
16 cancer 
PMID:  
18297132 
There was not a change 
in UGT1A expression 
among smokers and non-
smokers regardless of 
their health status.  
The highest expression 
was detected in smokers 
with lung cancer 
(p<0.05). 
GSE19027 Affymetrix Human Genome 
U133A Array 
 
Bronchial epithelium 17 healthy,  
 9 cancer  
8 healthy,  
12 cancer  
3 healthy  PMID: 
 20689807 
When heathy individuals 
were analyzed, all 
common UGT1A 
probesets showed a 
significant increase in 
current smokers was 
observed while the 
expression in former and 
never smoker were 
similar to each other 
(FDR<0.16). 
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A comparison among 
cancer patients showed 
that there was a fold 
change of 1.5 among 
current and former 
smokers with lung 
cancer. 
 
Table 5.4 A dataset comparing heavy and light smokers 
Array 
Name 
Platform Origin of tissue/cells Heavy 
Smokers 
Light 
Smokers 
Citation Result 
GSE12585 Affymetrix Human Genome 
U133A Array 
Lymphocytes 10 13 None Common UGT1A probesets 
detected a considerable 
expression, which did not 
change among heavy and light 
smokers. The expression of 
UG1A8-1A9 was almost at 
basal level. 
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Overall, the re-analysis of publically available data showed us that the epithelial cells 
in close contact with exogenous compounds showed a response to smoking by 
induction of UGT1A expression. By the analysis of UGT1A8-1A9 specific probes, 
we hypothesize that either of these genes might not be expressed or detected by the 
given microarray probeset thus is hard to evaluate with respect to their contribution 
to drug metabolism in oral, nasal and airway epithelia. Even though the picture 
showed difference in two datasets (GSE16149, GSE8987) the discrepancy may result 
from the low number of samples used in these arrays. The reason why these datasets 
have contradicting results with all the other may be because UGT expression and 
glucuronidation could be restricted to certain parts of a tissue 103 and the later 
datasets have isolated the samples from unrelated part of the tissue. Moreover, the 
interindividual variance in UGT1A expression, which has been shown before 104-105 
could be a reason for this contradiction. 
Arrays with current smoking status of the patients demonstrated that UGT1A 
upregulation in airway epithelia can be reversible as it is in the case with former 
smokers.  
The members of the immune system do not show a response to smoking in terms of 
UGT1A expression. Yet, their expression was detected in all datasets. In fact, there is 
a study revealing the expression of UGTs in bovine alveolar macrophages and 
bronchial epithelia 94. Furthermore Tochigi (2005)106 showed that UGT1A enzymes 
are induced in an isoform-specific manner in peritoneal macrophages in rat as a 
response to polycyclic aromatic hydrocarbons.  It can be proposed that UGTs in 
immune system may be expressed in a constitutive manner but not in an inducible 
state. This in turn supports the notion that upregulation of UGT1A enzymes requires 
a close contact of cells with the xenobiotics and the participation of the 
corresponding tissue in drug metabolism.  
When it comes to carcinoma cells; however, one microarray experiment presented a 
picture in which cancer cells were not responsive to smoking. On the contrary, the 
other array showed that there was a significant difference among current and former 
smokers with cancer. In order to comment on these contradicting results, the part of 
the tissue from which the samples were collected should be known precisely. The 
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reason is that, as stated above, drug metabolism could be carried out by restricted 
cells in a tissue. In addition, it has been demonstrated that drug metabolism enzymes 
were downregulated in certain cancer types, which in turn results in elevated 
resistance to chemotherapeutic drugs 107. Furthermore, in some cancerous cells drug 
metabolism enzymes are upregulated as in the case of healthy individuals 92. 
However, there is a common outcome of these two datasets, which is smoker cancer 
patients have the highest UGT1A expression (p<0.05; FDR<0.05). This picture is 
consistent with expectations, further supporting the relation between smoking and 
UGTs. 
Previous studies reported higher risk of colon cancer with smoking 108-109. In 
addition, Hübner et al. (2009)77showed that smoking upregulates UGT1A4 and 
UGT1A6 expression in small airway epithelia of healthy individuals 77. Nicotine, on 
the other hand, is the major addictive component in cigarettes. Moreover, 30% of 
nicotine metabolism is merely carried out by UGT enzymes. Therefore, testing 
whether nicotine is one of the driving forces in the relationship between smoking and 
UGT expression is logical.  
 Wong et al. (2007)110, has shown that nicotine upregulates proliferation of HT-39 
colon adenocarcinoma cells in a dose-dependent manner 110. With the purpose of 
experimenting whether nicotine had the same effect on SW620 colon 
adenocarcinoma cells, our group performed an MTT analysis 78. What was observed 
is that nicotine triggered the proliferation of SW620 cells only when they are serum 
starved 111.  
Based on this outcome, a microarray performed in our lab was re-analyzed 
exclusively for the UGT1A probesets used also for the re-analysis study in regard to 
smoking status. Functional analysis of the data has shown that glucuronidation was 
one of the pathways upregulated when SW620 cells were serum starved and  treated 
with 1uM nicotine (p<0.05) but not when treated with 10% serum replenishment78. 
This suggested that increase in UGT1A activity was unique to nicotine although it is 
not known how nicotine induces UGT1A expression. 
As mentioned before, there is a handicap of the genomic organization of UGT1A 
locus, disabling the analysis of the expression of each isoform by microarray. 
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Therefore, it was not possible to propose a specific isoform/isoforms that are being 
differentially regulated with nicotine and serum starvation treatments. Moreover, 
because UGT1A gene products share a high sequence similarity, either Northern Blot 
or Western Blot is not an ideal method to analyze their expression. Quantitative 
Real-time PCR analysis utilizing a well-designed unique primer pairs, on the other 
hand, is a robust approach to detect even the small changes in mRNA transcripts of 
each product.  
With the advent of Real-time PCR technology, it is possible to quantify mRNA 
expression levels precisely in a given cell line, as a response to any physiological 
conditions in a very short time 59. Real-time PCR is a highly preferred technique 
since it includes quite sensitive Taq polymerases, requires very small amounts of 
RNA template and does not require post-PCR modulations 46. Nevertheless, the 
results of analysis and quantification can only be reliable when the markers of 
successful RT-PCR assay are completed.  
Since no reference genes were stated for SW620 cells when they were nicotine 
treated we first studied a stable set of reference genes. Therefore we determined the 
expression of five internal standards and saw that GAPDH is the gene with most 
stable expression. Ribosomal proteins that are shown to be good reference genes in 
some other conditions failed in this case 98.  
In addition, the efficiency values of each primer couple catalyzed by the enzyme that 
we used were determined individually. For this purpose, cDNA pools were generated 
by mixing different carcinoma cell lines and diluting them by 2 folds Table 4.22. 
Most of the efficiency results were close to 2, which were acceptable values. An 
efficiency value by UGT1A7 primer; however, could not be determined due to its 
low expression in cDNA pool analyzed, disabling the detection of five values in a 
row. Furthermore, a cDNA inhibitor may be present in some of the samples, 
disabling the annealing with these primers. Since the qRT-PCR primers should be 
designed to amplify small products, some of the primers we used might suffer from 
large amplicon inefficiencies. The primers used in this study were published in the 
literature and was used to make our results comparable with the previous ones and 
they have common reverse primers. New primer pairs specific to each isoform might 
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be studied for selected isoforms, e.g., UGT1A8 and UGT1A7, where amplicon size 
is large and/or in the presence of excessive dimer formation. 
After running of each experiment, dissociation curves for each well were analyzed 
individually to check if there was a single peak. Furthermore, these peaks were 
expected to show up around 80°-90°C, indicating double stranded DNA target. 
Moreover, all the products were run on Agarose Gel electrophoresis to see whether 
negative controls were free of DNA and each sample has a unique band at the 
expected sizes. Overall, in most of our samples, both technical replicates were of 
good quality although in a few runs, one technical replicate of the sample had to be 
removed based on the exclusion criteria set previously. However, there were two 
cases in which a biological replicate had to be eliminated for analysis due to a 
detection failure in both replicates of either control or nicotine samples. These 
scenarios were observed with UGT1A7 and UGT1A9. These could stem from a 
technical error or due to large sizes of amplicons. What’s more, we used the 
automatic set for treshold calculations determined by the ABI 7500 Software itself. 
Treshold values can be manually placed, as well. Indeed, we noticed that fold 
changes might change even minimally when changing the threshold. 
Microarray experiments previously performed suggested that 1µM nicotine affects 
cell proliferation and induces a large scale transcriptomic response under starvation 
but not in the presence of serum78. 1uM nicotine has been selected since it represents 
the maximum amount of nicotine in smokers blood stream 112. In the present thesis, 
we have checked the expression levels of two genes that are known markers of cell 
proliferation, ANLN and MKI6. Previously, it was shown that overexpression of 
ANLN was associated with growth of lung carcinoma both in vivo and in vitro 100. In 
addition, it was speculated that ANLN was phosphorylated by PI3K/AKT pathway, 
which nicotine was known to activate 113-114. Furthermore, a recent study showed that 
MKI67 were among the genes whose expression increased when human airway 
epithelial cells were exposed to tobacco toxins for short term 115. Based on these, 
lack of upregulation of ANLN nor MKI67 with nicotine exposure in SW620 cells in 
the presence of serum points out that nicotine does not affect SW620 cells under 48h 
exposure unless when they are under stress. On the other hand, it is possible to see 
the statistically significant upregulation of both ANLN and MKI67 genes when cells 
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were treated with nicotine in presence of 0.1% FBS. This clearly shows that stress 
caused by quiescence enhances nicotine’s effect on cells. 
After verifying that there is an induction of growth with nicotine in serum starved 
cells, we desired to analyze the expression levels of each UGT1A isoform in those 
cells. Significantly deregulated isoforms after Bonferroni correction were: UGT1A1, 
UGT1A3, UGT1A4 and UGT1A6 (p<0.05). However, UGT1A5, UGT1A7, 
UGT1A9, UGT1A10, were not significantly changed using the primers previously 
published. These results were novel in that UGT1A expression has not been analyzed 
in detail in SW620 cells. In addition, specific circumstances (e.g. serum starvation) 
promoting nicotine’s short term effects have not been shown before, as well. It 
should be noted that the expression values for UGT1A7, UGT1A9, and UGT1A10 
were quite low thus it is difficult to clearly comment on their status. Therefore, new 
primers could be designed to confirm these findings. In addition, qRT-PCR 
optimization might be useful to reduce the dimer formation and increase duplicate 
reliability in the qRT-PCR runs.  
Furthermore, a qRT_PCR run with normally grown SW620 cells for UGT1A1 and 
UGT1A6 expression analysis showed that there was no change in their expression 
with increasing concentrations of nicotine. All together, these data has certain 
consequences, which can be stated as: 
- UGT1A isoforms did not respond to varying concentrations of nicotine at 2 days in 
the presence of serum. 
- Nicotine exposure elevated mRNA levels of particular UGT1A isoforms only in 
starved SW620 cancer cells . 
- There was a fine tunning effect of nicotine on UGT1A expression, modulating the 
levels in upregulation of each isoform. 
In broader context, it can be stated that: 
- The drug responsiveness of UGT enzymes was promoted under serum starvation 
conditions.  
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- Since modulations in UGT1A enzyme levels might affect the response to other 
drugs, smoking status of cancer patients together with enzyme expression patterns 
might be evaluated before use of therapeutics.  
We have confirmed the expression of most of the UGT1A genes in a colon cancer 
cell line as indicated in previous reports 2,20 In addition, UGT1A5 was detected to be 
the one with the highest expression in SW620 colon adenocarcinoma cells. 
UGT1A4 and UGT1A9 are the isoforms thought to be the principle isoforms for 
nicotine clearance by glucuronidation 43. These reactions predominantly take place in 
liver. Studies with intestinal and liver microsomes show that N-glucuronidation of 
nicotine in intestine constitutes less than 2% of the reactions taking place in liver 72. 
This is strong evidence pointing out that the isoforms responsible for nicotine 
glucuronidation are not expressed highly in intestine. In addition, UGT1A7, A8 and 
A10 are considered to be the potential enzymes of colonic glucuronidation since they 
are not expressed in liver 21. However, their expression status in SW620 cells has not 
been identified before. Re-analysis of microarray datasets with samples with known 
smoking status indicated that probeset specific to UGT1A9 was expressed in low 
levels in bronchial and airway epithelial tissue and can not be assessed accurately. 
Similarly, UGT1A9 does not seem to be affected with nicotine administration in 
SW620 cells. These suggest that either new primers needed to be studied in this 
context or changes might be due to posttranscriptional modifications. 
The isoforms that are upregulated by nicotine within 48h in serum starved SW620 
cells belong to bilirubin-type UGT1A enzymes except UGT1A6. Nevertheless, a 
common substrate for all these isoforms is absent. There are potential hypotheses to 
understand the coordinate upregulation of these particular isozymes. First of all, fine 
tuning by nicotine may result from the sequence similarity in that group of exons. In 
deed, in silico promoter analysis of all isoforms showed that the one group of exons 
shares a high sequence similarity, including all the genesupregulated in our 
experiments. In addition, this may stem from a simultaneous regulation by the same 
regulator. This hypothesis can be explained as follows: 
UGT enzymes are expressed in their host tissues both in a constitutive and inducible 
manner. The constitutive expression of UGTs is carried out by specific regulatory 
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proteins in that tissue. As an example, hepatocyte nuclear factor 1 (HNF1) is 
necessary for whole-time expression of UGT1A1, UGT1A6, UGT1A7 in liver 116-117.  
By comparison, there are regulatory receptors responding to hormones, xenobiotics 
and stress signals mediating UGT1A transcription and enzyme capacity 118. 
Following a ligand binding, these regulators bind to the corresponding response 
elements (antioxidant response elements (ARE) or/and xenobiotic response element 
(XRE)) located in the promoter regions of UGTs inducing their transcription. Among 
those, nuclear receptors constitutive androstane receptor (CAR) and pregnane X 
receptor (PXR) are found 119-120. In addition, the nuclear receptor peroxisome 
proliferator-activated receptor α (PPARα), the aryl-hydrocarbon receptor (AhR) and 
nuclear factor erythroid 2-related factor 2 (Nrf2) control UGT1A expression at 
trancriptional level, as well.  
Senekeo et al. has shown that UGT1A1, UGT1A3, UGT1A4 and UGT1A6 can be 
indcucable through PPARα regulatory element in human liver microsomoses 121. In 
addition, Barbier et al. (2003)122 showed that UGT1A9 transcription was induced by 
PPAR α ligands. 
Sugatani et al. (2008)123 claim that CAR ligands activate UGT1A1 isoform. In 
addition, it has been shown that there are two CAR activators regulating UGT1A5 
and UGT1A6 transcription in addition to UGT1A1’s in only liver 124.  
UGT1A1, UGT1A3, UGT1A4 and UGT1A6 are known to be regulated by aryl 
hydrocarbon receptor (AHR) agonists 31,125-127. Furthermore, UGT1A9 has been 
shown to be induced by AHR-agonists in Caco-2 cells 128. These suggest that AHR 
and PPARα might underlie the effects of nicotine and could be tested experimentally 
in future studies. These outcomes also are interesting since there have been reports 
correlating AHR with upregulation of proliferation. One study suggests that when 
overexpressed, AHR elevates E2F/DP2 activation, promoting cell proliferation in 
human lung carcinoma cell A459 129. In addition studies showing that mice with 
constitutive AHR expression develop stomach tumors 130.  Considering nicotine has a 
proliferative effect on starved SW620 cells, the relationship between UGT1A 
expression and proliferation could be further studied with respect to potential 
transcription factor regulation. 
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PXR and its variants predominantly regulate UGT1A1, UGT1A3 and UGT1A4 
genes in HepG2 and Caco-2 cells. What is striking about this nuclear receptor is that 
nicotine is one of the ligands activating PXR 131. 
It has been shown that induction of UGT1A8 and UGT1A10 requires simultaneous 
modulation by AHR and Nrf2 132. But it should be noted that there is an extensive 
crosstalk between all regulatory elements inducing UGT1A transcription in a 
coordinated manner 133. 
What’s more MEME analysis of the promoter regions of UGT1A genes presented a 
bunch of motifs, some of which are specifically present in certain genes. In case 
when these motifs are analyzed further, a part of the puzzle of fine tuning by nicotine 
can be revealed.  
One other hypothesis is that epigenetic regulators may modulate UGT1A expression 
coordinately. It is possible that there may be a common epigenetic regulator that acts 
on UGT1A1, UGT1A3, UGT1A4, UGT1A5 and UGT1A6 as a response to nicotine. 
Indeed Gagnon et al. (2006) 134 showed that UGT1A1 is subjected to epigenetic 
regulation 134 . Furthermore, it has been documented that nicotine interacts with 
methyltransferases 135. 
Each UGT isoform has its distinct substrate specificity, being determined by the 
unique Exon I. Some substrates are precisely selective for a certain UGT enzyme. 
For example, individuals with homozygous mutant UGT1A1 allele suffer from 
hyperbilirubinemia, which is defined as the deficiency in bilirubin metabolism 4. This 
clearly indicates the critical role of UGT1A1 in bilirubin metabolism. By 
comparison, most of the endo and exogenous substrates of UGT1A family overlap 
with each other.  
Since another UGT member can compensate for the activity of a member with low 
activity, it is not possible to assign a specific isoform for the metabolism of a specific 
drug 136. Accordingly, it is not possible to speculate that exposure to a certain drug is 
responsible for the upregulation of a specific isoform’s expression.  
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Our results indicate that the drug responsiveness of UGT enzymes was promoted 
under serum starvation conditions only. Serum starvation causes cells to undergo 
quiescence, a stage at which cells try to keep their ROS (reactive oxygen species) 
levels lows 137. Nrf2 is a well-known regulator transcription factor for UGT1A genes. 
As Kalthoff et al. (2010)132  has shown that Nrf2 was upregulated in response to 
increased ROS levels, this transcription factor may well be induced after serum 
starvation. Our microarray and re-analysis of GEO datasets have shown that 
probesets annotated to Nrf2 were not among the ones significantly changed (p<0.05). 
However, Nrf2 could be additionally regulated by posttranslational mechanisms.  
In broader context, our report states that cells become more responsive to nicotine 
when they are deprived of serum. In physiology, it may have an implication as 
follows: As known, tumor tissues are mass of highly heterogenic cell populations. In 
this mass structure there are cells in contact with extracellular matrix, supplied with 
nutrients, growth factors and O2. However, there are also cells closed within this 
mass, surrounded with cells and deprived of nutrients as well as serum. Nicotine may 
not induce growth in cells facing outside within 48h; nevertheless, cells found in this 
mass may have been well induced by nicotine within a short time.  
Nicotine clearance from the body is an important criterion for assessing the effect of 
this compound. The rate of nicotine metabolism shows interindividual variance and 
is affected by several factors; such as, diet, age, gender, medication, and smoking 38. 
Moreover, it has been shown that lung cancer incidences are lower in slow nicotine 
metabolizers 138. This observation points out the importance of nicotine metabolism 
enzymes in to what extend this compound exerts its effects on cells.  
Studies indicate that fast metabolism is related with higher exposure of cells to 
nicotine and its effects. Since upregulation of nicotine metabolism is also associated 
with smoking, 139 any factor that promotes these metabolic pathways forms a risk.  
Another implication of our results is that smoking may deregulate drug metabolism. 
How xenobiotic metabolism is affected by smoking is critical because its promotion 
or suppression may modulate the response to other drugs. In other words, enhanced 
xenobiotic metabolism may result in a resistance to chemopreventive drugs and 
therapies, which is undesirable. Indeed, heavy smokers were shown to bear increased 
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glucuronidation catabolism of paracetamol 140 In addition, the correlation between 
Camptothecin resistance and upregulation of UGT1A activity has been shown in 
colon cancer cells 141. 
Irinotecan, a camptothecin compound, is used in systemic treatment of metastatic 
colorectal cancers 142-145. The mode of action of irinotecan is that, by the inhibition of 
Topoisomerase I, DNA adducts accumulate resulting in cell death 104.  The active 
metabolite of irinotecan, SN-38, is inactivated by the actions of UGT enzymes; 
namely, UGT1A1, UGT1A6, UGT1A7 and UGT1A9 146-149.     
In literature, it has been well documented that the anticancer response and toxicity of 
irinotecan change widely from individual to individual. The efficacy and possible 
toxicity of irinotecan drug has been correlated with the polymorphisms in UGT1A 
gene cluster 104-105. In addition, Gagnon et al. (2006)134  has shown that epigenetic 
silencing in the promoter region of UGT1A1 gene is correlated with lower activity 
and thus, irinotecan toxicity. Furthermore, cigarette smoking decreases the exposure 
of cells to irinotecan and the efficiency of its related treatment 150. 
 The overall scheme shows that polymorphisms, smoking and epigenetic mechanisms 
causing low activity of UGT enzymes may bring about toxic effects of the drug in 
addition to an anticancer response in the patients 104. The reason speculated for this 
phenotype is that lower metabolic activity causes higher plasma concentrations of the 
drugs 151.  Consequently, these drugs can stay at plasma for longer and affect cells 
more efficiently.  
Our finding showed that UGT1A1 and UGT1A6, the isoforms most affected by 
irinotecan, also were highly affected by nicotine exposure in SW620 cells. This 
suggests that irinotecan and nicotine might use similar isoforms for glucuronidation 
thus nicotine exposure might predict partially the drug response.  
In a study, where the transcriptome of methotrexate-resistant breast cancer cells is 
compared with that of sensitive cells, UGT1A6 was found to be significantly 
overexpressed in MTX-resistant cancer cells 152. The increase in mRNA transcript 
and enzymatic activity of UGT1A6 has been well defined and proposed to be the 
reason for the reduced cytotoxicity by MTX. de Almagro et al. (2011)152 showed that 
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when UGT1A6 expression was abolished by siRNA treatment, on the other hand, the 
resistance to MTX was not reduced. This is very good evidence showing that 
UGT1A isoforms could exhibit redundancy in their substrate specificity. Moreover, 
an increase in sensitivity could only be observed when whole UGT1A family was 
targeted with a siRNA, verifying the hypothesis 153. 
Besides, deregulation of UGT enzymes may have critical toxicological and 
physiological consequences for the patient. In case when the expression of an 
isoform is changed due to an exposure of a drug, the bioavailability of various 
nutrients and drugs, which are subjected to glucuronidation, would be changed, as 
well 152. Therefore, the possibility of crossresistance between nicotine and other 
chemotherapeutic drugs should be taken into account in tumor treatments. 
In conclusion, UGT1A expression when analyzed in an isoform specific manner can 
provide a more powerful profile of a drug’s metabolism rather than analyzing a 
single isoform. 
Of great importance there are studies showing that there is a gender difference in 
terms of response to smoking. It is indicated that smoker women are more prone to 
lung, oral cavity and oropharynx cancer than smoker men 154-156. In addition, women 
are shown to be faster metabolizers than men 157-158. In fact, xenobiotic metabolism 
was shown to be affected by factors, such as sex, as well.  For example, since women 
generate higher amounts of estrogen, estradiol metabolizing enzymes, among which 
there are UGT1A isoforms, should be upregulated in women 86,159. This can explain 
why smoking women might be more prone to developing cancer than smoking men. 
Additionally, expression of UGT enzymes has been shown to be determined by sex 
160.  
In introduction, tissue specific expression section aims to precisely present the 
expression profiles of all UGT1A isoforms tissue by tissue. However, it is clearly 
seen that their expression can sometimes be detected and sometimes not, pointing out 
the fact that there is interindividual variability. This variability may be the result of 
genetic polymorphisms 161, epigenetic modifications 134 or any error related with the 
techniques used. Moreover, it was shown that UGT expression was restricted to 
certain cell types or regions in an organ by immunohistochemical studies. For 
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example UGT1A expression has been shown to be restricted to the proximal and 
distal convoluted tubules, the loops of Henle, and the collecting ducts in kidney 103.  
Therefore, rather than tissues, efforts should be spent to analyze the individual’s 
expression patterns. 
Based on what was presented in this report, it is possible to propose that cancer 
patients should be analyzed in terms of their gender, smoking status and UGT1A 
expression in advance to any drug therapy. 
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6. FUTURE PERSPECTIVES 
Finding out what regulates the expression of the isoforms should be the primary task 
following the data presented in this thesis. It is clear that regulation of UGT1A gene 
cluster is sensitive to serum levels and hence, starvation conditions either depleting 
growth factors and/or inducing quiescence/apoptosis might lead to production of a 
transcription factor responsible for induction of UGT1A transcription. However, it is 
important to note that serum starvation by itself does not induce UGT1A 
transcription but only in combination with nicotine. Future studies should include 
whether in the presence of absence of this TF nicotine is effective in inducing 
transcription of UGT1A gene cluster. 
Due to redundancy in substrate specificity of UGT1A isoforms, it is hard to 
discriminate the contribution of each isoform in the metabolism of a substrate 152. In 
addition, no inhibitory chemicals or antibodies are available for the isoforms 136. 
Future studies should include using liver or colon microcosms to see the activity of 
these enzymes. Western blot or immunohistochemistry studies might also be helpful 
in defining isoform specificity in response to nicotine. Furthermore, in vivo analysis 
of UGT1A expression could be carried out. 
Other drugs with a similar induction profile could be explored to prevent any 
crossresistance cases that can be observed in drug therapies. 
Making a new setup of experiments including chronic nicotine treatment to observe 
the effects of this compound in long term would be another route to follow.
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